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ABSTRACT
THERAPEUTIC POTENTIAL OF WITHAFERIN-A AGAINST NON-SMALL CELL
LUNG CANCER:
Al Hassan Kyakulaga
August 29th, 2019
Lung cancer remains the leading cause of cancer-related deaths among both men
and women worldwide, and in the United States. Non-small cell lung cancer (NSCLC)
represents about 85-90% of all lung cancer cases and has an overall five-year survival
rate of only 17%. Since 60-70% of NSCLC patients are diagnosed when the tumors are at
an advanced stage, chemotherapy remains the most viable treatment option for NSCLC.
Recently, the development of molecularly targeted drugs and the breakthrough
immunotherapies have shifted the front-line therapies for NSCLC from cytotoxic
chemotherapy towards an era of personalized medicine. However, due to the high genetic
and cellular heterogeneity of NSCLC tumors, these revolutionary therapies are not
applicable in >70% of NSCLC patients. Moreover, regardless of treatment approach,
dose-limiting toxicity and drug resistance are major therapeutic challenges in treatment of
advanced NSCLC. Therefore, there is a significant unmet clinical need to develop highly
efficacious therapeutic options for the treatment of advanced NSCLC. In this dissertation,
studies were performed with the overall objective of determining the therapeutic potential of
withaferin A (WFA), a plant-derived steroidal lactone anticancer compound against NSCLC.
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Briefly, the preclinical efficacy, toxicity and pharmacokinetic properties of WFA were
investigated using in vitro and in vivo models. Two human NSCLC cell lines, H1299, and
A549 were used to investigate the antitumor efficacy of WFA, alone or in combination with
paclitaxel (PAC), a standard chemotherapeutic agent used for the treatment of various types
of cancer. Firstly, we found that WFA alone significantly inhibited (IC50: 0.3-0.6 µM) the
growth, proliferation, colony formation, adhesion, migration, and invasion of both H1299
and A549 cells. As reported elsewhere, the antitumor activities of WFA were both time- and
concentration-dependent, but were completely abrogated in the presence of thiol-containing
compounds such as N-acetyl cysteine (NAC) and dithiothreitol (DTT). Importantly, the
combination of PAC and WFA at 1:40, 1:20, and 1:10 ratios, respectively, resulted in
synergistic inhibition of tumor cell growth and proliferation for both H1299 and A549 cell
lines. Comparatively, the PAC+WFA combination displayed greater anticancer efficacy and
potency than cisplatin (cis-Pt) alongside PAC (cis-Pt+PAC) or cis-Pt+WFA, and it resulted in
a >40-fold decrease in the IC50 of PAC against both H1299 and A549 cells. In addition, using
PAC or taxol resistant cell lines (TR-A549), we demonstrated that WFA was active against
the growth and proliferation of chemotherapy resistant human NSCLC cells both in vitro and
in vivo. Mechanistically, WFA induced apoptosis, modulated the expression of MDR-1, as
well as inhibited the induction of epithelial-to-mesenchymal transition (EMT) in A549
NSCLC cells via the regulation of Smad2/3 and NFκB signaling. In the toxicity evaluation,
we found that oral administration of up to 12 mg/kg of WFA was well tolerated with no signs
of systemic and histopathologic toxicity in male SD rats. Also, a highly sensitive,
reproducible and robust HPLC-MS/MS method for the detection and quantification of WFA
in plasma and tissues was developed. Pharmacokinetically, WFA displayed a high plasma
protein binding capacity (>95%) and high in vitro intrinsic clearance (Clint: 88µL/min/mg) in
SD rat liver microsomes. Following a single intravenous bolus dose (10 mg/kg), plasma
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concentration-time profile of WFA showed a very rapid clearance from plasma (t1/2 = 37
min). Together, the findings presented in this dissertation demonstrate the therapeutic
potential of WFA, and provide a strong rationale for the further studies to develop WFA
alone or its combination with standard chemotherapeutic agents such as PAC for the
treatment of advanced NSCLC and other cancer types.
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CHAPTER ONE
INTRODUCTION

Lung Cancer
Lung cancer is the leading cause of cancer-related deaths among both men and
women worldwide [1, 2], and in the United States [3]. In 2018, there were about 2.1 million
new cases (about 11.6% of all cancer cases) and 1.76 million deaths due to lung cancer
reported worldwide [4]. In the United States, approximately 234,030 new cases (121,680
men and 112,350 women) and 154,050 deaths (83,550 men and 70,500 women) due to
lung cancer were estimated to have occured in 2018 [3]. On the basis of these statistics,
more people have died from lung cancer than from breast, pancreatic, prostate and colon
cancers combined [3, 5]. This extremely poor prognosis from lung cancer is driven in part
by the complexity and biological aggressiveness of lung tumors [5-7]. In addition, the
majority of lung cases are either locally advanced or highly metastatic at the time of
diagnosis [8] and are never curable regardless of treatment approach [9, 10]. Thus, although
there have been notable improvements in the progression-free survival rates, the overall
survival from lung cancer has remained dismal [3]. Therefore, unless new treatments are
developed, there remains a significant unmet clinical need for the development of clinically
effective therapeutic strategies to change the current clinical landscape of lung cancer.
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Clinically, lung cancer is a highly heterogeneous and complex disease, representing
a large group of tumor types that develop from cells in the lung tissue [5, 7, 11]. Although
there are many subtypes, lung tumors almost exclusively (>99%) develop from airway
epithelial cells [7] and are generally termed as carcinomas. The high tumor heterogeneity,
coupled with the biological aggressiveness of lung cancer make the treatment choices very
difficult, subjective and ineffective [9, 11, 12]. As such, to effectively treat these multiple
lung cancer subtypes is a major challenge which demands a spectrum of treatment options
and approaches. Additionally, lung tumors are largely asymptomatic in the early stages [6,
11] and as a result are mostly diagnosed when the disease is at an advanced stage. Thus,
despite the advancements in imaging techniques and molecular diagnostics, current clinical
reports indicate that 60-70% of lung cancer cases are diagnosed at stage III-IV [3, 13].
Since curative surgery is not applicable in patients with advanced lung cancer, almost all
stage III-IV lung cancer patients succumb to the disease within a year of diagnosis [9, 13].
Unfortunately, even among patients that present with early-stage disease, there are very
high tumor relapse rates which contribute to high mortality rates [14].
Based on the cellular histology (Fig. 1.1), the World Health Organization (WHO)
classifies lung cancer as either small-cell lung cancer (SCLC) or non-small cell lung cancer
(NSCLC) [5, 10]. In the US and worldwide, NSCLC tumors account for 80-90% of all lung
cancer cases [3]. The SCLC tumors primarily occur among heavy smokers and appear as
small round-shaped tumor cells, with visible mitotic patterns, granular nuclear chromatin
and absent nucleoli [6, 7]. On the other hand, NSCLC tumor cells are much more complex
[5] and are further sub-divided into three main subtypes; adenocarcinomas, squamous-cell
carcinomas and large-cell carcinomas [15]. Currently [5], adenocarcinomas are the most
2

prevalent subtype of NSCLC [2, 10] and these present as glandular or mucin-producing
cells. Histologically, the appearance of tumor cells in adenocarcinomas is such that the
cells are arranged as; (a) acinar, (b) papillary, (c) bronchoalveolar, or a mixture of these
growth patterns (Fig. 1.1) [10]. Contrastingly, the appearance of squamous cell carcinomas,
the second most prevalent subtype of NSCLC, is such that the cells display intercellular
bridges and/or keratin. Finally, large-cell carcinomas, the third subtype of NSCLC are
visualized as large tumor cells containing vesicular nuclei and prominent nucleoli. Overall,
the high degree of cellular and genetic complexity of lung tumors make treatment options
extremely challenging and accounts for the poor prognostic outcomes [16, 17].
Etiologically, the carcinogenesis of lung cancer is a complex and multifactorial
process that is driven by an interplay of several environmental, genetic and lifestyle factors
[6, 10]. To date, cigarette smoking remains by far the major cause for lung cancer, and
worldwide statistics [1, 2, 10] show a significant positive correlation between smoking
patterns and lung cancer incidence rates. These data indicate that both active and sidestream (or the so called “passive”) smoking cause lung cancer [6, 7]. Quantitatively, the
risk for lung cancer increases with both the quantity and duration of smoking, and as such
is highest among those who smoke and never quit. In the United States, it has been
estimated that almost 90% of all lung cancer cases are attributable to cigarette smoking
[18] [3]. Chemically, cigarette smoke contains a complex mixture of many known
carcinogens (such as benzo[a] pyrene and, nitrosamines) [6, 7]. In susceptible individuals,
exposure to these carcinogens cause specific genetic mutations and/or epigenetic changes
in cells that result in alteration of cellular-signaling mechanisms. Studies have shown that
early in the carcinogenic process [6], these changes in cell signaling mechanisms confer a
3

proliferative advantage to a small group of lung epithelial cells that are later progressively
transformed into highly malignant lung tumor cells [7, 11]. In addition to carcinogens in
cigarette smoke, other risk factors for lung cancer include exposure to asbestos, chromium,
arsenic, nickel, cadmium, beryllium, silica, and radon gas [10].

Fig 1.1. Histologic classification of Lung Cancer.
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The NSCLC Staging system
The staging of cases at diagnosis is very critical in the treatment of NSCLC.
Currently, the choice of therapeutic strategy and the expected clinical prognosis for
NSCLC are mainly dependent on the stage of the disease at diagnosis. The most widely
utilized and recommended staging criteria for NSCLC tumors at first diagnosis is the
Tumor-Node-Metastasis (TNM) system (Table 1). In this staging system, the NSCLC
tumors are assigned a series of descriptors or scores which enable oncologists to group the
NSCLC tumors into seven clinical stages that reflect the expected clinical outcomes [11].
Numerical clinical scores are assigned to the size of the primary tumor (T), the presence of
tumor metastases in the regional lymph nodes (N) and in distant organs (M) [19, 20].
Together, the combination of these scores allows the NSCLC cases to be grouped into the
seven stages; IA, IB, IIA, IIB, IIIA, IIIB, and V. For prognostic purposes, the NSCLC cases
assigned to stages IA, IB, IIA, and IIB are generally considered to be in the early-stages
of the disease. For these early-stages of NSCLC, the primary tumors are associated with
no evidence of local or distant metastases [20, 21]. On the other hand, NSCLC cases that
display tumor descriptors which fall into the stages III-V display evidence of metastatic
nodules in the regional lymph nodes and/or distant organs. Therefore, the stages III-V of
NSCLC are considered to be advanced stages of the disease Un and these usually have the
worst survival outcomes [20]. Unfortunately, in the clinic, the majority of NSCLC cases
(60-70%) are diagnosed when the tumors are at stage IV-V and are considered to be
advanced NSCLC.
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Table 1. The TNM NSCLC Staging System

Stage

TNM

Stage 0

Carcinoma in situ

Stage 1A

T1 N0 M0

Stage 1B

T2 N0 M0

Stage IIA

T1 N1 M0
T2 N1 M0

Stage IIB

T3 N0 M0
T3 N1 M0
T1 N2 M0

Stage IIIA

T2 N2 M0
T3 N2 M0
T4 N0 M0
T4 N1 M0
T4 N2 M0

Stage IIIB

T1 N3 M0
T2 N3 M0
T3 N3 M0
T4 N3 M0

Stage V

Any T, Any N, M1
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The Treatment of NSCLC
Once the stage of NSCLC is established, the next step is the determination of the
most appropriate course of treatment for each patient on a case by case basis. In the clinic,
the treatments for NSCLC comprise of surgical removal of part or whole of the lung tissue,
radiation, and systemic chemotherapy either alone or in combination [6, 13]. Per the TNM
descriptors, the therapeutic goal for early-stage NSCLC is to cure the patients of the
primary tumors. Therefore, for patients that are diagnosed with early stage NSCLC,
curative surgery is the standard treatment of choice and this patient population represents
those in whom the best clinical outcomes are expected. Indeed, multiple clinical reports
have shown that cure of the primary tumors is reportedly attainable in up to 80% and 50%
for stage I and stage II cases, respectively [13]. Unfortunately, only about 20-25% of all
NSCLC cases are at an early stage (I-II) at diagnosis [2]. Moreover, many of these patients
are above 60 years of age and comorbidities such as pulmonary and cardiac disease are not
uncommon. As such, in greater than 50% of early-stage NSCLC patients, surgery is not
practical because of the poor overall health condition of the patients or what is clinically
referred to as performance status [6]. Furthermore, it is also widely reported that relapse
rates in NSCLC after surgery are in excesses of 70% within 6-12 month. Therefore, surgery
by itself is never a sufficient and effective therapeutic strategy for the treatment of NSCLC
and most patients require supportive systemic therapies [13, 18, 22].
Systemic chemotherapy remains the cornerstone in the management of NSCLC in
the neoadjuvant, adjuvant and/or palliative settings. Regardless of the stage of NSCLC at
diagnosis, almost all NSCLC patients benefit from some form of systemic therapy during
the course of the treatment. However, since surgery is not option for patients with advanced
7

NSCLC chemotherapy remains the treatment of choice. The main clinical objectives of
systemic chemotherapy in advanced NSCLC are to; (1) manage the symptoms, (2) prolong
patient survival, and (3) maintain or improve the patient’s quality of life. Today, the
systemic therapeutic options for NSCLC fall into three broad categories: (1) platinumbased combinations, (2) molecularly targeted drugs, and (3) immune checkpoint inhibitors.
Before the selection of the systemic chemotherapeutic regimen in NSCLC, patients are
evaluated for several important factors such as tumor histology, patient performance status,
the presence of metastasis, and the status driver mutations. Given the biological complexity
of NSCLC tumors, no single systemic treatment has been proven clinically effective and
as such, the choice of the course of treatment has remained subjective and mainly
dependent on the toxicity profile of the drugs used. In the current WHO guidelines,
systemic therapy for NSCLC recommends a combination of multiple drugs with different
mechanisms of action and therapeutic targets to maximize efficacy, and minimize the risk
of overlapping toxicities.
Previously, the choice of systemic chemotherapy for NSCLC was solely dependent
on the stage and patient performance status without regard to the differences in the
histological subtypes. However, two very significant clinical findings transformed the
treatment choices for the various histological subtypes of NSCLC. Firstly, it was observed
that the anti-angiogenic agent bevacizumab was differentially toxic among NSCLC with
different tumor subtypes. Secondly, in multiple clinical trials it was determined that
pemetrexed, a folate anti-metabolite antitumor agent was ineffective in patients with
squamous cell carcinoma (SCC), a subtype of NSCLC. Although detailed molecular
mechanisms have not been elucidated for these observations, together, these two novel
8

clinical findings permanently changed the treatment approaches for the different subtypes
of NSCLC. Consequently, while adenocarcinoma, squamous cell carcinoma, and large cell
carcinomas are all NSCLC, they each have slightly variable treatment approaches.
In the past decade, the landmark discoveries that revolutionalized the treatment
approaches for NSCLC were the molecular identification of activating mutations in genes
such as the EGFR and ALK in adenocarcinomas. The discovery of driver mutations in the
EGFR and ALK genes have unearthed and fueled the development of new therapeutic
paradigms for NSCLC in the form of molecularly targeted drugs. Subsequently, we have
witnessed an evolution of molecularly targeted therapies such as tyrosine kinase inhibitors
(TKIs) and their accelerated FDA approval as first-line therapies for advanced NSCLC.
The introduction of TKIs into the clinic have tremendously shifted the therapeutic options
of NSCLC towards an era of personalized medicine. However, these drugs have also been
largely ineffective because only 20-30% of NSCLC cases harbor ‘targetable’ driver
mutations. In addition, besides the high cost of therapy, targeted drugs only offer marginal
and temporary improvements in clinical response mainly due to the rapid development of
drug resistance and the widely observed disease progression while on treatment.
Specifically, small molecules targeting mutations in the EGFR gene have become
very popular as frontline treatments for advanced NSCLC adenocarcinomas. In the US,
EGFR mutations represent approximately 10-15% of adenocarcinoma patients, the most
prevalent of which is exon 19 deletions and mutations in exon 21. Extensive molecular
studies have showed that these EGFR pathway-activating mutations promote cellular
proliferation and the expression of antiapoptotic mechanisms, which together promote
tumor progression [14, 25]. For such patients, agents targeting EGFR mutations have
9

become the first-line therapies for NSCLC adenocarcinoma. In this class of anticancer
agents, Gefitinib was the first TKI targeting EGFR mutations to receive accelerated FDA
approval in 2003 as monotherapy for locally advanced or metastatic NSCLC. Gefitinib was
found to be highly effective in NSCLC patients with tumors haboring EGFR mutations
after the failure of both platinum-based and docetaxel therapies. In 2004, another EGFR
inhibitor, Erlotinib was the first oral anti-EGFR TKI agent to be approved by the FDA for
the treatment of advanced NSCLC after treatment failure by platinum-based therapies.
Later, the agents such as afatinib, osmertinib, and rociletinib all of which target EGFR have
been approved, and alongside gefitinib and erlotinib are recommended as the first-line
chemotherapeutic agents for the treatment of advanced NSCLC adenocarcinoma with
EGFR activation mutations. Unfortunately, almost all patients who are treated with these
anti-EGFR drugs experience disease progression within 2 years [17]. Although patients
initially show favorable clinical responses, about 50-60% rapidly develop secondary EGFR
mutations and lose the sensitivity of EGFR TKIs.
On the other hand, the American Cancer Society (ACS) estimates that ALK-EML4
gene fusions are present in about 2-7% of NSCLC patients. In previous clinical trials, it
was found that patients who harbor ALK rearrangements did not benefit from therapy with
EGFR TKIs. Subsequently, this led to the development and approval in 2011 of crizotinib,
an oral ALK inhibitor that produced response rates of up to 57% in ALK-positive cases.
Thereafter, ceritinib and alectnib, both of which are more potent ALK inhibitors than
crizotinib, have been approved for the treatment of ALK-positive NSCLC, especially in
patients with tumors that are resistant to crizotinib. In addition to EGFR and ALK targeting
drugs, other targeted therapies against HER2 mutations (trastuzumab), BRAF (dabrafenib),
10

RET rearrangements (cabozantinib) and angiogenesis (bevacizumab) are also approved for
the treatment of advanced NSCLC [17, 25, 26].
The most recent breakthrough therapeutic strategies for the treatment of advanced
NSCLC are the immunotherapies. These new anticancer agents are mainly premised on the
restoration of dysregulated immune system responses against cancer cells in patients [27,
28]. Unlike chemotherapy, immunotherapies indirectly target tumor cells by stimulating
the individual patient’s immune system mechanisms to attack tumors [6]. In general, there
are two approaches to immunotherapy of cancer namely, (1) the vaccination and (2) the
immune-checkpoint approaches. In the vaccination approach, antigens or cells are used to
stimulate T-cells to eliminate tumor cells. Today, vaccines against EGF, TGFβ, and PD-1
are at different stages of advanced clinical testing with promising findings and their
possible introduction to the therapeutic armamentarium against NSCLC in the near future
[4]. On the other hand, the immune-checkpoint approach utilizes specific monoclonal
antibodies to neutralize specific tumor molecular pathways [4, 14]. The two most
prominent drug targets for immune checkpoint inhibitors are: the cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4) and programmed cell death protein-1 (PDL-1). In 2015,
pembrolizumab and nivolumab, both of which are monoclonal antibodies, received FDA
approval for the treatment of metastatic NSCLC. Based on the results of the landmark
KEYNOTE clinical trials, it has been determined that pembrolizumab is highly effective
in patients expressing PDL-1 on greater than 50% of tumor cells. Consequently, nivolumab
and pembrolizumab have become the standard therapeutic strategy for patients with PDL1 overexpressing squamous and non-squamous advanced NSCLC.
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However, in the greater majority of NSCLC patients, tumors do not show targetable
driver mutations. For these patients, the first-line systemic therapies are platinum-based
combination chemotherapies [6]. These treatments are administered as two or more drug
combinations consisting of a platinum compound

(such as cisplatin or carboplatin)

alongside a second or third-generation chemotherapeutic agents. Usually, based on the
patient’s clinical status, four to six cycles are administered while monitoring the clinical
response and toxicity profile. Today, the most common antitumor agents used alongside
the platinum drugs are: paclitaxel, docetaxel, gemcitabine, pemetrexed or vinorelbine [18,
23]. These various drug combinations have been found to show similar clinical efficacies
and the choice of treatment is mainly dictated by patient factors and toxicity profile [6, 24].
Clinically, it appears that the cisplatin-taxane therapies although are associated with greater
toxicity potential, have consistently provided higher clinical response rates. In many
treatment guidelines, a two-drug combination of cisplatin and paclitaxel are recommended
as the standard regimen for stage IIIB-IV lung cancer with 1-year survival rate exceeding
40% [4, 24]. More recently, because of the lower toxicity profile of gemcitabine, a threedrug combination (in addition to cisplatin and paclitaxel) has also become popular but with
minimal increments in overall patient survival [24]. In patients with non-squamous
carcinoma, pemetrexed is recommended as the third drug to the cisplatin-paclitaxel
combination and survival rates are between 13-14 months [6].
In summary, the targeted drugs and immunotherapies have revolutionalized the
systemic therapies for NSCLC. However, platinum-taxane combinations still represent the
the gold standard in the treatment for advanced NSCLC. Unfortunately, these drugs also
represent a major pathway towards the development of chemoresistance and metastasis.

12

Withaferin A
Withaferin A (WFA) is a member of a large group of naturally occurring 28 carboncontaining compounds collectively called the withanolides [19]. These withanolides (Fig.
1.2) are structurally composed of a steroidal framework to which a lactone ring is attached
and are sometimes referred to as ‘steroidal-lactones’ [20]. The steroidal part of
withanolides consists of network of 4-cycloalkane rings, 3-cyclohexane rings, and 1cyclopentane ring. The second part of withanolides, the lactone ring, is a cyclic ester which
is appropriately oxidized to form a 6-membered ring [19]. This overall basic withanolide
structure can be modified either in the steroid framework or the side chains to yield a
myriad of compounds. As such, more than 300 different withanolides have been isolated
and characterized [21]. Of all these compounds, WFA is the most potent and was the first
member of the withanolides to be isolated from the Solanaceae species.
Chemically, WFA is a 4β, 27-dihydroxy-1-oxo-5β, 6β-epoxywitha-2, 24-dienolide
and was first isolated from alcoholic extracts of the Indian Ayurvedic medicinal plant
Withania somnifera [20, 22-24]. The isolation of WFA from W. sominfera was prompted
mainly by the systematic scientific review of the antitumor activities of Indian Ayurvedic
medicinal plants of which W. somnifera, which is also known as Ashwagandha, or Indian
ginseng is a popular medicinal plant in the Ayurvedic system. Traditionally, the different
parts of W. somnifera are used to prepare various types of herbal formulations. Several
preclinical studies were conducted demonstrating the anticancer effects extracts of W.
somnifera (L.). Most notably, Devi et al., showed that intraperitoneal (i.p.) administration
of alcoholic root extracts of W. somnifera significantly inhibited the growth of sarcoma180 xenografts in nude mice [23]. In addition, studies also demonstrated the inhibitory
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effects of W. somnifera on chemically-induced fibrosarcoma and skin tumors in Balb/C
mice [25]. These studies provided the rationale and fueled the investigation and isolation
of the bioactive constituents of W. somnifera, which were found to be the withanolides. In
1965, the first and major withanolide, WFA was isolated from alcoholic extracts of the
leaves of W. somnifera. Later, WFA was isolated from other species such as Withania
aristata, Dunalia spinose and Vassobia breviflora [21, 24].
Following the isolation of WFA as a crystalline compound alongside its dihydroderivative from leaves of W. somnifera, its partial and final chemical structures of WFA
were first solved by Lavie et al., [20, 23, 24]. In its basic chemical structure (Fig 1.2),
WFA is composed of an ergostane framework to which a lactone ring is attached. The
lactone ring in WFA is a cyclic ester composed of 5-carbon atoms, in which the carbon
atoms at C-22 and C-26 are oxidized to form a 6-membered ring [26]. This unique
arrangement of atoms in the WFA structure results in five chemically active functional
groups. These groups include; the unsaturated ketone ring, a hydroxyl group at C-4,
epoxide ring between C-5 and C-6, a hydroxyl group at C-27, a 6-carbon lactone ring, and
an unsaturated carbonyl group [27, 28]. Through these functional groups, WFA has the
ability to interact with multiple molecular targets, particularly proteins, resulting in several
pharmacological activities [22, 29]. Currently, review of the literature shows that WFA has
antitumor, anti-inflammatory, antiangiogenic, cardioprotective, immunomodulatory,
hepatoprotective, anticonvulsant and anabolic effects [21, 29]. In spite of these multiple
effects, WFA has attracted significant testing mainly for its anticancer activity [22].
The anticancer activity of WFA has been a subject of interest for many researchers
around the world. Today, several published studies have explored the antitumor efficacy
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of WFA using cell culture, xenografts and orthotopic tumor models of multiple human
cancers [22, 28-30]. In most of these studies, WFA has been found to possess proapoptotic, cytotoxic, anti-invasive and anti-migratory effects against multiple tumor cell
types. Mechanistically, WFA regulates several molecular targets in tumor cells including
enzymes, signaling molecules and other proteins crucial to the survival of cancer cells [19,
29]. Results from structure-activity studies have consistently demonstrated that three
positions in the WFA structure are critical for its interaction with sulfhydryl groups of
cysteine residues of proteins [27]. These three positions include; (1) the unsaturated ketone
(C-3) in the A-ring, (2) the epoxide group at C-5, and (3) the lactone ring [27].
Recently, spectral analysis of the WFA structure has revealed that C-3 position in
the unsaturated A-ring is the main target for thiol group binding [31]. In fact, it has been
hypothesized that the sulfhydryl groups of cysteine residues react with C-3 via ‘MichaelAddition’ alkylation type of reactions to form covalent bonds [28, 32]. These type of
reactions are thought to play a major role in the ability of WFA to inhibit several signaling
molecules in cancer cells. Furthermore, other studies have demonstrated that the epoxide
ring between C-5 and C-6 is the most critical for the cytotoxic anticancer effects of WFA.
For example, in vitro studies have shown that the reaction of WFA and 2-mercaptoethanol,
which specifically affects the 5,6-epoxide structure, resulted in the loss of anticancer
activity. Similarly, the incubation of WFA with strong reducing agents like N-acetyl
cysteine (NAC) and dithiothreitol (DTT) resulted in the loss of the pro-apoptotic activity
of WFA [33]. In other studies, it has been reported that the loss of unsaturation in the Aring caused loss of anti-inflammatory and antiangiogenic effects of WFA [21, 34].
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In the preclinical setting, several studies have demonstrated the antitumor effects
of WFA against various cancer types. Briefly, there is evidence to show efficacy of WFA
against melanoma, breast, lung, prostate, ovarian, thyroid and gastrointestinal cancers.
Perhaps, of all these, the most extensively investigated type of cancer for which WFA has
shown excellent activity is breast cancer. For this canvcer type, multiple lines of evidence
using different tumor models from independent studies indicate that WFA is proapoptotic
in estrogen-sensitive (MCF-7) and estrogen-independent (MDA-MB-231) breast cancer
cells in vitro [35]. To corroborate these in vitro findings, in vivo studies conducted using
nude mice have reported statistically significant inhibition of the growth of subcutaneous
MDA-MB-231 xenografts. Similarly, WFA has also attenuated the growth and metastasis
of orthotopically implanted 4T mouse mammary tumor cells [31, 36]. Furthermore, using
clinically-relevant transgenic animal models for breast cancer, WFA reportedly inhibited
more than 50% of palpable tumor growth in MMTV-neu mice [36, 37].
In addition to breast cancer, preclinical efficacy for WFA has been demonstrated
against prostate, ovarian, and cervical cancers. For example, intraperitoneal administration
of WFA (4-8 mg/kg/day) for 24 days resulted in over 70% inhibition of PC3 subcutaneous
tumor growth in mouse models [38]. Here, the inhibition of tumor growth by WFA was
attributed to the inhibition of proteasomal activity and subsequent induction of apoptosis.
In another independent study, 3-5 mg/kg of WFA administered orally to transgenic mice
for 39 weeks, inhibited tumorigenesis and metastasis of prostate adenocarcinoma [39].
Also, WFA alone or in combination with other drugs has shown excellent efficacy against
cervical cancer and ovarian cancers. Data from in vitro and in vivo studies indicate that
WFA has the capability of inhibiting the growth of human cervical cancer cells. It was
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found out that the antitumor activity of WFA in cervical cancer cells was related to the
downregulation of the human papillomavirus oncogenes E6/E7, resulting in the induction
of p53 and apoptosis [40]. More recently, the intraperitoneal administration of WFA alone
or as a combinatorial agent alongside cisplatin to nude mice bearing A2780 human ovarian
cancer cell xenografts resulted into 70-80% reduction in tumor growth and complete
inhibition of metastasis [41-43]. Together, these data demonstrate the potential efficacy of
WFA against gynecological cancers and further highlight the potential of WFA as a
potential chemotherapeutic agent.
To date, the molecular mechanisms of action underlying the antitumor activity of
WFA remain elusive. Nonetheless, there is a growing body of molecular mechanistic data
which provides insights into the molecular targets of WFA in tumor cells. The actions of
WFA can be summarized based on four (4) major activities of WFA in tumor cells. These
include (1) proapoptotic effects, (2) antiproliferative activities, (3) antimetastatic and antiinvasive effects, and (4) cancer stem cell targeting effects. It has been shown that the
proapoptotic effects of WFA are mainly mediated via the reactive oxygen species (ROS)dependent mechanisms, endoplasmic reticulum (ER) stress-dependent mechanisms, and
the regulation anti- and pro-apoptotic proteins in tumor cells. On the other hand, WFA’s
effects on cellular proliferation are mainly mediated via G2/M cell cycle arrest-dependent
mechanisms, such as the regulation p21 and cyclin-dependent kinases. In summary, current
available evidence shows that WFA is a multifactorial antitumor compound with the ability
to interact with a myriad cellular targets. The most plausible hypothesis postulates that the
antitumor effects of WFA are mediated by molecular mechanisms involving the interaction
of WFA and cellular proteins via thiol oxidation.
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1.5 Statement of goals
The overall goal of this doctoral thesis was to investigate the therapeutic potential
of WFA, a plant-derived steroidal lactone against NSCLC. Briefly, studies were designed
to explore the preclinical antitumor efficacy, toxicity and pharmacokinetic properties of
WFA. Two human NSCLC cell lines, H1299 and A549 were used to evaluate the in vitro
and in vivo efficacy of WFA alone or in combination with standard chemotherapeutic drugs
such as PAC and cis-Pt against the growth and proliferation of human NSCLC cell lines.
In addition, a PAC-resistant (TR-A549) cell line was used to explore the potential of WFA
for targeting drug resistance in NSCLC. Finally, the potential repeated-dosing toxicity and
pharmacokinetic properties of WFA were investigated in male SD rats to evaluate the
disposition characteristics of WFA. In order to accomplish these research goals, the
following specific aims were explored;
Aim 1. To determine the synergistic effects of WFA alongside PAC on the growth
and proliferation of human NSCLC cells in vitro.
Aim 2. To investigate the effects of WFA on epithelial-to-mesenchymal transition
(EMT) and chemoresistance in human NSCLC cells
Aim 3. To determine the potential 28-day repeat-dose toxicity and the
pharmacokinetics properties of WFA in SD rats.
Overall, the findings from the above studies advance a novel strategy of using WFA
either alone or in combination with PAC as an effective strategy for targeting human
NSCLC cells. These studies provide a strong rationale for conducting further studies to
develop WFA as a clinically useful anticancer agent for the treatment of NSCLC and other
cancers.
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CHAPTER TWO
SYNERGISTIC COMBINATIONS OF PACLITAXEL AND WITHAFERIN A
AGAINST HUMAN NON-SMALL CELL LUNG CANCER CELLS
INTRODUCTION
Lung cancer remains the leading cause of cancer-related deaths among both men
and women in the U.S [44]. This extremely poor prognosis is explained in part by three
main characteristics of lung cancer: a) distant organ metastasis at diagnosis, b) a high
degree of cellular and genetic diversity, and c) rapid development of drug resistance [15,
45]. Clinically, NSCLC represents 80-85% of all the cases of lung cancer and has an overall
five-year survival rate of 15% [17, 46]. The therapeutic options for NSCLC are dependent
upon the clinical stage at diagnosis [46-48] with surgical resection being the standard of
care for early-stage NSCLC [49]. In early-stage NSCLC, the cure of the primary tumors is
usually attainable in up to 80% and 50% for stage I and stage II cases, respectively.
However, about 60-70% of the NSCLC cases are either locally advanced or extensively
metastatic at the time of diagnosis [5, 13]. Thus, systemic chemotherapy [14, 50] remains
the cornerstone therapeutic strategy for the treatment of early-stage and advanced cases of
NSCLC.
Decades of clinical trials have demonstrated that the use of chemotherapy relieves
disease symptoms and improves the quality of life in NSCLC patients [9]. Recently,
landmark discoveries of driver genetic mutations have fueled the development and FDA
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approval of targeted [9, 51] and immunotherapies [52, 53]. Following the introduction of
these treatments into the clinic, the frontline therapies for advanced NSCLC have been
shifted and revolutionized towards an era of personalized medicine [12, 53, 54]. Yet,
besides their high cost, the targeted drugs and immunotherapies only benefit small and
specific groups of NSCLC patients. This is primarily true because less than 30% of all
NSCLC patients show targetable mutations [55], and anti-PD-1 drugs are only effective
among patients with tumors expressing PDL-1 on >50% of tumor cells [56]. Therefore,
despite these recent therapeutic advancements, NSCLC remains largely incurable, and the
overall clinical benefit of current therapies in NSCLC is marginal and temporary [46, 48].
Platinum-based therapies are the first-line regimens used for neoadjuvant, adjuvant
and in the palliative setting for advanced NSCLC [16, 57]. Upon diagnosis, NSCLC
patients with no targetable driver mutations are usually administered with four-six cycles
[57] of platinum-based chemotherapy. Two platinum compounds, cisplatin or carboplatin
are used as the main drugs used to treat advanced NSCLC. These platinum compounds
have nonspecific mechanisms of action [58] and induce apoptosis in both tumor and normal
cells via the formation of DNA adducts. Mechanistically, cisplatin or carboplatin passively
diffuses into cells and once inside the cell, one chloride ion is removed from the platinum
compound and is replaced by a water molecule. Then, the hydrated platinum agent enters
the nucleus, where it forms strong covalent bonds with purine bases, particularly guanine
in DNA. The binding of the cisplatin or carboplatin with guanine residues creates
intrastrand crosslinks, which cause extensive unrepairable DNA damage, and subsequently
induce apoptosis. Of the two platinum drugs, cisplatin shows the highest antitumor efficacy
but produces the most significant toxicity in the form of nephrotoxicity as well as the
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irreversible and often untreatable neurotoxicity. Although effective as monotherapies,
platinum drugs are administered as combination chemotherapy alongside a thirdgeneration chemotherapeutic agent [13, 14, 16, 57].
The two-drug taxane-platinum chemotherapeutic combinations represent the
standard of care as platinum-based systemic treatments for advanced NSCLC [9, 59].
Taxanes as a novel class of anticancer agents is a large group of compounds that target
microtubules inhibiting spindle formation and blockade of mitosis during cell division [60].
Paclitaxel (PAC), the most prominent taxane, was first isolated from extracts of the bark
of Taxus brevifolia (Pacific Yew Tree) in 1964. Unlike other tubulin inhibitors, PAC’s
mode of action [61] involves the binding to and preventing microtubule disassembly, thus
causing mitotic arrest, and the induction of apoptosis. In NSCLC, PAC displays greater
antitumor potency than cisplatin (cis-Pt) against all subtypes NSCLC [14]. Unfortunately,
since PAC displays variable clinical pharmacokinetics, primarily due to its hydrophobicity,
it requires large doses. Thus, although highly efficacious, the cis-Pt+PAC chemotherapy
suffers dose-limiting toxicity and the clinical efficacy has plateaued at about 10 – 14
months.
In the present study, we tested a novel therapeutic strategy to enhance the antitumor
efficacy of PAC against NSCLC cells through combination with withaferin A (WFA).
WFA (Fig. 1a), a member of the withanolides, is a plant-derived anticancer compound that
was first isolated [23] from extracts of the Indian Ayurvedic medicinal herb, Withania
somnifera (Ashwagandha). In the recent past, WFA has attracted significant preclinical
testing [22] mainly for its antitumor activity against lung [40, 62-65], breast [31, 35, 37],
uterine and cervix [66], ovarian [43], pancreatic [67], B-cell lymphoma [68]. In the present
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study, we have demonstrated that at various combinatorial ratios, WFA alongside PAC is
highly synergistic against the growth and proliferation of human NSCLC cells.
Specifically, our data indicated that PAC+WFA synergistically inhibited colony formation,
migration, invasion and induced apoptosis in both drug-sensitive and drug-resistant human
NSCLC cells. When combined, WFA caused a dramatic increase in the efficacy and
potency PAC against both H1299 and A549 cells. Using the combination index (CI) and
dose-reduction index values, we found PAC+WFA to be more synergistic than PAC+cisPt or cis-Pt+WFA. In fact, we achieved up to a 40-fold reduction in the IC50 of PAC at a
1:40 constant ratio of PAC to WFA. In summary, this study demonstrates the potential
therapeutic efficacy of WFA alone, and in combination with PAC against NSCLC cells
and provides a strong rationale for advancing this combination in clinical trials.
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MATERIALS AND METHODS
Drugs, chemical supplies, and reagents
Withaferin A (purity, > 95%) was provided as a gift sample by 3P Biotechnologies
(Louisville, KY, USA), paclitaxel (Cat # P-9600) was purchased from LC laboratories
(Woburn, MA, USA), cisplatin (cis-diamine platinum [II] dichloride, Cat # P4394) and
2.3% crystal violet solution (Cat # HT90132) were purchased from Sigma Aldrich (St.
Louis, MO, USA). MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide,
Cat #L11939 ) was purchased from Alfa Aesar (Ward Hill, MA, USA) while dimethyl
sulfoxide (DMSO, Cat #13390) was purchased from Electron Microscopy Sciences
(Hatfield, PA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM, Cat #10569044),
RPMI medium 1640 (Cat # 11875-095), 0.25% Trypsin-EDTA (Cat # 25200-072),
antibiotics (100 U penicillin/100 mg streptomycin, Cat# 15140), and ultrapure distilled
water (Cat #10977-015) were purchased from Life Technologies (Grand Island, NY, USA).
Heat-inactivated fetal bovine serum (FBS, Cat# 12306C)) was purchased from SAFC (St.
Louis MO, USA). Pierce RIPA cell lysis buffer (Cat #89901), 100x halt
protease/phosphatase inhibitor cocktail (Cat #7844), Pierce BCA protein assay kit (Cat
#23225), PVDF-transfer membrane (Cat#88518), Spectra Multicolor broad range protein
ladder (Cat #26634) and Pierce ECL Western Blotting Substrate (Cat # 32106) were
purchased from ThermoScientific (Rockford, IL, USA). Bolt 4-12% Bis-Tris phosphate
gels (Cat #NW04125Box, NW04120Box, NW04122Box) and 20x Bolt MES running
buffer (Cat# B002) were purchased from Life Technologies (Carlsbad, CA, USA). The
FITC-AnnexinV/PI Apoptosis Assay kit (Cat#V13242) was purchased from Life
Technologies (Eugene, OR, USA). Primary monoclonal antibodies (against β-actin, PARP,
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P21, Bcl2, Bax, phospho-histone3, phospho-cdc2, cyclin E2, cyclin B1, cyclin A1, cleaved
–caspase 3, cleaved-caspase-7, cleaved-PARP) as well as secondary antibodies (antimouse IgG and anti-rabbit IgG) were purchased from Cell Signaling Technology, Inc.
(Danvers, MA).
Cell lines and culture conditions.
The human NSCLC cell lines, H1299, and A549 cells were obtained from
American Type Culture Collection (Manasa, VA, USA). Previously developed [69, 70]
PAC- resistant NSCLC cells (TR-A549) were kindly provided by Dr. Bruce Zetter (Boston
Children’s Hospital, Boston, MA, USA). These cell lines were maintained in either DMEM
or RPMI 1640 culture media (10% FBS, 1% antibiotics) for A549 and H1299 cells,
respectively. The cultures were incubated at 37°C in a 5% CO2 humidified incubator and
passaged at 80% confluence for less than 20 cycles.
Drugs and treatments.
Stock solutions of PAC, WFA, and cis-Pt at concentrations of 5 mM were prepared
by dissolving in 100% DMSO at 25 °C. The stock solutions for each drug were stored dried
in aliquots of 40 µL at -20°C until used in subsequent experiments. Cells were incubated
with the drugs after diluting the stock concentrations of each test agent in cell culture media
to desired concentrations. In all treatments, DMSO was kept at a maximum of 1% in the
vehicle and test treated groups.
MTT cell viability assay.
Cell viability was measured using the MTT colorimetric assay. Briefly, A549 or
H1299 cells were seeded in 96-well plates and incubated at 37°C overnight to allow
attachment. Following cellular attachment, the cell culture media was discarded and
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replaced with fresh cell culture media containing different concentrations of drugs/agents.
These cells were incubated with the drugs for designated periods and then incubated with
cell culture media containing 0.5 mg/mL MTT reagent solution. After 3 hours, the MTT
containing media was discarded and the purple formazan crystals in each well were
solubilized using 200 µL of DMSO. The absorbance of the resulting solution was
determined spectrophotometrically by measuring the optical density (OD) at 570 nm. The
OD values of the solution in the wells containing untreated cells were considered as 100%
cell growth and used as a reference to calculate the percent growth of other wells. The
arithmetic mean of 3 technical replicates was calculated at each concentration of PAC and
WFA alone and in combination to obtain the percent cell viability. Data were expressed as
meanSD of more than 3 separate experiments.
Colony formation assay
To perform the colony formation assay, H1299 and A549 cells were seeded in 6well tissue culture plates at a density of 500 cells/well in 2 mL of medium (10% FBS) and
incubated in a 37 °C humidified atmosphere containing 5% CO2 for 24 h. The cells were
then incubated in culture medium containing different concentrations of either PAC or
WFA, alone and in combination for 24 h. The drug-containing medium was replaced with
fresh drug-free medium. After 7 d, the plates were washed with sterile PBS, and the cells
were fixed using methanol/acetic solution (3:1) for 5 mins and stained with 0.5% crystal
violet (in methanol) for 15 min. The crystal violet solution was carefully removed, the
plates were rinsed in a stream of running water and left to air dry at room temperature. The
number of colonies in each well was counted under a microscope.
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Apoptosis analysis by flow cytometry.
Apoptosis was detected using the Annexin V/ propidium iodide (PI) assay. Briefly,
H1299 and A549 cells were treated with PAC, WFA alone, and in combination for 24 h.
Both floating and attached cells were collected, washed twice with ice-cold PBS and resuspended in 100 µL of Annexin-binding buffer at a cell density of approximately 1 x 106
cells/mL. To each 100 µL of cell suspension, 5 µL of FITC-Annexin V and 1 µL of 100
µg/mL PI solution was added and incubated for 15 minutes in the dark. After incubation,
400 µL of Annexin binding buffer was added to each Annexin V/PI stained cell suspension
and analyzed for fluorescence using a flow cytometer by measuring the fluorescence
emission at 530 nm and >575 nm. A total of 10,000 cells were counted in each cell
suspension, and the data were analyzed using FlowJo software (Trista, CA, USA) to obtain
the percent early and late apoptotic cells.
Cell migration and motility assays.
The wound-healing assay was performed to assess cell migration and motility. This
was accomplished using the 2-well culture inserts (ibidi®) following the manufacturer’s
instructions. Briefly, ibidi® culture inserts were placed in 6-well plates and 3 x 105 cells/ml
were seeded into each of the two chambers of the same insert. The cells were incubated in
the inserts for 24-h to obtain confluent monolayers and the inserts were removed to create
a wound area (gap) between the two cell growth areas. Floating and dead cells were
removed by washing the cells twice using culture media, then media containing PAC or
WFA alone and in combination was added. Cellular migration and motility were assessed
using a bright-field microscope at 0 and 24 h. The migrated cells were photographed using
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a microphotographic camera, and the cell-covered areas were measured using WimScratch
software program (Wimasis, Munich, Germany).
Transwell migration and invasion assay.
Cell migration and invasion assays were performed using the transwell culture
inserts that were pre-coated with or without 40 μL of 3.0 mg/mL Matrigel (BD). H1299
cells (4 x 104) suspended in 200 µl of the serum-free medium in the presence and absence
of test agent(s) were seeded onto the upper compartment of the transwell chamber. The
lower chamber was filled with 600 μL of media supplemented with 10% FBS as an
attractant to cause cell migration. After 24 h incubation, cells on the upper surface of the
transwell insert were removed using a cotton swab. The migrated cells at the bottom of the
insert were fixed using 4% paraformaldehyde, permeabilized using 100% methanol and
stained using 0.2% toluidine blue (in 1% sodium borate). The number of migrated cells
were counted under the light microscope.
Western blot analysis.
Whole-cell protein lysates were prepared using RIPA buffer as per the
manufacturer’s instructions. The total protein concentration was determined using BCA
assay and an aliquot of 20 µg total cellular protein of each sample was resolved by SDSPAGE on 4-12% Bis-Tris gels. The separated proteins were transferred to PVDF
membranes, and these membranes were blocked using 5% non-fat dry milk in TBST for 1
h. To determine the relative expression of specific proteins, membranes were first probed
with primary antibodies followed by the respective HRP-conjugated secondary antibodies.
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The expression levels of each protein were determined by visualizing the protein bands
using the chemiluminescent Pierce ECL western blotting reagent.
Tumor xenograft studies in nude mice
Taxol resistant NSCLC cells (TRA549 cells) were used to determine the in vivo
efficacy of WFA. Female athymic nude (nu/nu) mice (5–6-week old) were purchased from
Charles Rivers Labs and were maintained in accordance with the Institutional Animal Care
and Use Committee (IACUC) guidelines. Briefly, TR A549 cells (2.5 × 106 cells/mouse)
in 100 µL (50:50) of serum-free media mixed with Matrigel matrix (Becton Dickinson,
Bedford, MA) were subcutaneously injected into the left flank of each mouse. The mice
were provided purified AIN-93M diet and water ad libitum. Once the average tumor size
reached about 80-120 mm3, the mice were randomly divided into 3 groups (n = 5) and
treated with vehicle, PAC (10 mg/kg divided in 3 doses per week) and WFA (10 mg/kg)
as 3 doses per week. All treatments for the vehicle control and intervention drug groups
were done via intraperitoneal injections (i.p) and the tumor volumes were measured twice
weekly.
Statistical analysis.
Statistical analysis was performed using Graph Pad Prism 8.0 (La Jola, CA) and
CalcSyn 2.0 (Biosoft, Cambridge, UK). Data are presented as means ± SD of at least 3
separate experiments. To determine the synergistic interaction between PAC and WFA, the
dose-effect data on percent cell viability was analyzed by the combination index (CI)
method described by Chou et al.[71]. The CI values; CI<1, C=1 and C>1 indicated
synergism, additive and antagonism, respectively.
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RESULTS
WFA inhibits the proliferation of NSCLC cells via thiol oxidation
To determine the antiproliferative effects of WFA alone (Fig. 2.1a) on NSCLC
cells, we first evaluated its in vitro antitumor effects on monolayers of two human NSCLC
cell lines. Briefly, H1299 cells (large cell carcinoma) and A549 cells (adenocarcinoma)
were seeded in 96-well plates (3000 cells/well) and incubated with WFA (0 – 5 µM) for 3
- 72 h. The relative cell viability of both cell lines was measured after 72 h incubation by
the MTT assay. By considering the vehicle treated cells as 100% cell viability, WFA
significantly decreased the the viability of both H1299 and A549 cells in a dose- and timedependent manner (Fig. 2.1b and Fig 2.1c). The median inhibitory concentrations (IC50)
for WFA as calculated by median-effect equation method using CalcuSyn software were
in the sub-micromolar range (0.20 - 0.68 µM) for both H1299 and A549 cell lines. The
efficacy (>90% inhibition) for WFA was observed at when cells were incubated with WFA
for 48 h and 72h. In either cell lines, the concentrations of WFA ≥ 2 µM resulted in >90%
inhibition of cell proliferation at 48 h and 72 h. To support the MTT data, we next examined
whether WFA induced apoptosis in H1299 and A549 cells. Since we observed using the
MTT assay that concentrations of WFA ≥2 µM produced maximum efficacy, we chose this
dose level to investigate the ability of WFA to induce apoptosis. The cells were incubated
with or without 2 µM WFA for 24 h and apoptosis induction was determined using
Annexin-V/PI staining assay. Our data (Fig. 2.1d) indicated that WFA when compared to
the vehicle-treated cells significantly increased the percentage of Annexin V positive cells,
an indicator of induction of apoptosis. The induction of apoptosis was further confirmed
by performing western blot analysis (Fig. 2.1e),where we found a dose-dependent increase
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in the activation (cleavage) of caspase-3, an increase in the expression of p21 and phosphoHistone 3 (p-H3), all of which were indicative of apoptosis.
Previously, studies have reported that the antitumor effects of WFA are dependent
on the generation of reactive oxygen species (ROS) in tumor cells. Indeed, the role of ROS
production as regards to the anticancer activity of WFA has been demonstrated in breast,
ovarian and melanoma tumor cells. Similarly, to further investigate this hypothesis, we
determined whether or not WFA induced the production of ROS in H1299 and A549
NSCLC cells. Briefly, cells were seeded in 6-well plates and incubated with 2 µM WFA
for 12 h. The generation of ROS was qualitatively determined by fluorescence microscopy
using H2DCFDA (Fig. 2.1f) and Mitosox Red (Fig. 2.1h) assays per manufacturer’s
instructions. Here, we found that the incubation of cells with WFA (2 µM) increased the
fluorescence intensity of H2DCFDA (green) and Mitosox Red (red) in both H1299 and
A549, an indicator of increased production of ROS (Fig. 2.1f and Fig. 2.1h). In this study,
hydrogen peroxide (H2O2, 100 µM) was used as a positive control. Interestingly, for both
cell lines, the concomitant treatment of cells with WFA alongside with N-acetyl cysteine
(2.5 mM) significantly inhibited the production of ROS. To further provide perspective on
the role of ROS production in the antitumor activity of WFA, we cultured both H1299 and
A549 cells with WFA in the presence of 3 known ROS quenchers; N-acetyl cysteine
(NAC), dithiothreitol (DTT) and Trolox. Interestingly, as has been reported elsewhere, the
thiol-containing compounds NAC (2.5 mM) and DTT (100 µM) completely abrogated the
anticancer activity of WFA against both H1299 and A549 cells. Contrastingly, Trolox, a
non-thiol- containing ROS quencher did not inhibit the antiproliferative activities of WFA
(Fig. 2.1g ).
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Fig 2.1. WFA inhibits the growth and proliferation of H1299 and A549 NSCLC cells via thiol
dependent induction of apoptosis. (a) The chemical structure of WFA. The cells were incubated
with WFA (0-5 µM) for 3, 6, 12, 48 and 72 h and the cell viability measured by MTT assay. WFA
time and dose-dependently inhibited the proliferation of H1299 (b) and A549 cells (c). The
induction of apoptosis following incubation with WFA (2 µM) was determined using annexinV/PI
assay (d) and western blot analysis (e). Briefly, WFA increased the percentage of annexin V
positive cells, the clevage of caspase 3, and the expression of p21 and p-H3. The generation of ROS
was measured the intensity of green fluorescence in the H2DCFDA assay (f) and red fluorescence
in the Mitosox Red assay (h). H2O2 (100 µM) was used as a positive control and N-acetyl cysteine
(NAC) was used to inhibit ROS. (g) The antiproliferative activity of WFA was inhibited in the
presence of thiol donors NAC (2.5 mM) and dithiothreitol (DTT) but not in the presence Trolox.
Where indicated, data are presented as mean ± SD of 3 technical replicates (*p<0.05).
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Synergistic effects of PAC, CisPt, and WFA on NSCLC cellular proliferation
In this study, we determined the potential synergistic effects of PAC, cis-Pt, and
WFA in H1299 and A549 cells in vitro. Firstly, we tested each of these agents as individual
drugs and then based on the relative potency of each compound in the preliminary findings,
we evaluated synergism using the following combinatorial ratios: 1:40, 1:100, and 10:1 of
PAC: WFA, PAC:cis-Pt, and cis-Pt: WFA, respectively. In H1299 cells, we demonstrated
that as individual drugs, PAC, cis-Pt, and WFA each dose-dependently inhibited the
cellular viability (Fig. 2.2a). By using median-effect plots (Fig. 2.2b), we determined and
compared the efficacy and potency of the three agents. We found that PAC displayed the
greatest potency (IC50: 43 nM), followed by WFA (IC50: 251 nM) and then cis-Pt (IC50:
8438 nM). Based on these data, we next assessed whether the combinations of each drug
with one of the other two compounds were synergistic against. Using the dose-response
data (Fig. 2.2d-f) and isobologram analyses (Fig. 2.2g-i), we found that the data points for;
PAC+WFA, PAC+cis-Pt, and cis-Pt+WFA were all below the lines of additivity at IC50,
IC75, and IC90. In addition, visual inspection of CI-Fa plots (Fig. 2.2j-l) showed that the CI
values at various effect levels were all <1. Therefore, as per the method of Chou et al., the
dose-response data, isobologram and CI values all indicated that three combinations;
PAC+WFA, PAC+cis-Pt, and cis-Pt+WFA were highly synergistic against H1299 cells,.
However, based on the dose-reduction index (DRI), we found that there was a 33-fold and
4-fold reduction in the IC50 of PAC against H1299 cells in the PAC+WFA and PAC+cisPt combinations, respectively. On the other hand, we found a 26-fold and 7-fold change in
the IC50 of cis-Pt when combined with WFA and PAC, respectively. For WFA, the IC50
were 5-fold and 8-fold less when combined with PAC and cis-Pt, respectively.
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Similarly, in A549 cells (Fig. 2.3), we also observed that PAC, cis-Pt, are WFA all
individually decreased cell viability in a dose-dependent manner. Based on the medianeffect plots (Fig. 2.3b), PAC displayed the lowest IC50 (11 nM), followed by WFA (IC50:
560 nM) and then cis-Pt (IC50: 5730). In terms of synergism (Fig. 2.3d-l), all combinations
tested for the 3 drugs resulted in data points at IC50, IC75 and IC90 below the lines of
additivity, indicating synergistic activity. As was observed in H1299 cells, the combination
of PAC+WFA resulted in the strongest synergism (PAC DRI: 83-fold) followed by cisPt+WFA (cis-Pt DRI: 22-fold) and PAC+cis-Pt (6-fold and 15-fold DRI for PAC IC50 and
cis-Pt IC50, respectively). Together, these compelling in vitro data strongly suggested that
the PAC+WFA combination was the most synergistic chemotherapeutic combination
against the two human NSCLC cell lines, H1299and A549.
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Fig 2.2. WFA synergized the antiproliferative activity of PAC and CisPt against H1299 cells.
The potency and efficacy of PAC, CisPt and WFA against NSCLC cells were compared using the
median-effect equation. (a) Dose-response plots depicting PAC, CisPt and WFA dose-dependent
inhibition of cell proliferation of H1299 cells. (b) Median-effect plot indicated PAC had lowest
IC50 followed by WFA and CisPt the highest. Preliminary combinations of PAC and CisPt, PAC
and WFA and CisPt and WFA were tested. PAC+WFA (c) displayed the greatest efficacy, followed
by CisPt + WFA (d). Isobologram analysis (g-i) and combinaion index (CI) values (<1) indicated
that all the combinations were highly synergistic against H1299 cells.
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Fig 2.3. WFA synergized the antiproliferative activity of PAC and CisPt against A549 cells.
The potency and efficacy of PAC, CisPt and WFA against A549 NSCLC cells were compared
using the median-effect equation. (a) Dose-response plots depicting PAC, CisPt and WFA dosedependent inhibition of cell proliferation of A549 cells. (b) Median-effect plot indicated PAC had
lowest IC50 followed by WFA and CisPt the highest. Preliminary combinations of PAC and CisPt,
PAC and WFA and CisPt and WFA were tested. PAC+WFA (c) displayed the greatest efficacy,
followed by CisPt + WFA (d). Isobologram analysis (g-i) and combinaion index (CI) values (<1)
indicated that all the combinations were highly synergistic against A549 cells.
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Synergistic effect of PAC and WFA on colony formation and induction of apoptosis
Next, to validate the observed MTT data, we sought to investigate potential
synergistic effects of PAC and WFA on the replicative ability of H1299 and A549 cells
using colony formation assay (Fig. 2.4). Briefly, cells (500 cells/well) were seeded in 6well plates and incubated in media containing PAC (0-25 nM) and WFA (0-1 µM) alone,
or their combination. As expected, PAC and WFA individually displayed dose-dependent
inhibition of colony formation in H1299 (Fig. 2.4a) and A549 (Fig. 2.4b) cells. As
expected, the combination of PAC and WFA synergistically inhibited colony formation in
both cell lines greater than either agent used alone. Our data (Fig. 2.4 c-e), indicated that
at shorter drug exposure durations resulted in much greater synergistic effects for PAC and
WFA than was observed when cells were exposed to drugs for extended drug periods (48,
72 h).
Further, we investigated whether the PAC + WFA combination induced apoptosis in
NSCLC cells. Cells were incubated with WFA (1.0 μΜ) or PAC (25 nM), alone and in
combination for 24 h, and apoptosis was detected by flow cytometry using the Annexin
V/PI assay. We found that the combinations of PAC and WFA significantly increased the
percentage of Annexin-V positive cells (Fig. 2.4f). To support these findings, western blot
was performed and the data obtained (Fig. 2.4g) indicated an increase in the cleavage of
both PARP and caspase-3, Bcl-2 degradation, and Bax upregulation. In addition, p21 and
phospho-H3 were found to be significantly increased, an indication of cell cycle arrest and
subsequent induction of apoptosis.
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The effect of different ratios, treatment schedules, sequence and cell numbers on the
synergism of PAC and WFA
As we found that PAC+WFA resulted in greater synergism than PAC+cis-Pt or cisPt+WFA against both H1299 and A549 cells, we further examined whether different
combination ratios, cell numbers, sequences and schedules of treatment would alter the
synergism. First, we used PAC as the standard of care and then altered the concentrations
of WFA to test the effects of different ratios of PAC: WFA on cell viability. Based on
previously obtained IC50 values, we tested combinations of PAC+WFA at 1:40, 1:20, and
1:10 ratios of PAC to WFA, respectively, on the viability of cells. For each of these ratios,
we examined the resulting CI and DRI values to assess the extent of synergism. Using
isobolograms, CI and DRI values, we found that all the ratios 1:40, 1;20, and 1:10 were
synergistic against both H1299 and A549 cells. For all the combinatorial ratios, the CI
values at 50% (ED50), 75% (ED75) and 90% (ED90) effect levels were all <1 indicating
synergism as per Chou et al.,. Since the 1:40 ratio of PAC: WFA produced the lowest
combined IC50 against both H1299 (3.6 nM) and A549 (7 nM), this combination was
concluded to have displayed the greatest potency and efficacy of PAC and WFA. In terms
of synergism, the highest synergistic interaction was displayed by the ratio of 1:10 of
PAC:WFA since it resulted in the lowest CI values compared to 1:20 and 1:40 (Table 2.1
and Table 2.2).
Next, we determined the most effective strategy for combining PAC and WFA to
maximize the synergism. We assessed the resultant synergism obtained when the cells were
exposed to both drugs; (1) concomitantly, (2) sequentially, and (3) in a schedule-dependent
manner. Firstly, and as expected, all the three treatment strategies (concomitant, sequential
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and schedule dependence) resulted in synergism of PAC and WFA against both H1299 and
A549 cells (Table 2.3). Importantly, we found that by pretreatment of cells with WFA (2
h) prior to incubation with PAC+WFA, the resultant synergism (CI=0.22 and 0.26 for
H1299 and A549 cells, respectively) was greater than that observed when cells were
pretreated with PAC prior to PAC+WFA (CI= 0.87 and 0.64) or the simultaneous of PAC
and WFA treatment (CI: 0.77 and 0.81). Interestingly, the synergism of PAC and WFA
was not schedule-dependent as there were no significant differences in the potency and
efficacy of either compounds when the drugs were added in a schedule-dependent manner.
Furthermore, we determined and compared the CI and DRI values obtained when cells
were incubated with PAC and WFA for various periods of time.
Further, we tested for the effects of PAC and WFA, alone and in combination on
different cell numbers of H1299 and A549 cells. Briefly; 2000, 4000, 8000 and 12000
cells/well were seeded in 96-well plates and incubated with increasing concentrations of
PAC and WFA, alone and in combination (Fig 2.5). The media containing drugs was
discarded after 12 h and the cells were incubated for up to 48 h to determine cell viability.
For both H1299 and A549 cell lines, there was a dramatic decrease in the individual
efficacy of PAC or WFA with an increase in the number of cells plated. As expected, the
lowest IC50 values for PAC and WFA were observed when incubated with 2000 cells/well
(Fig 2.5a and Fig 2.5e). However, when the cell numbers were increased to 12000
cells/well (Fig 2.5d and Fig. 2.5h), there was up to 40-fold and 8-fold increase in the IC50
of PAC and WFA, respectively against both H1299 and A549 cells. Interestingly, while
there was an increase in the combined IC50 values of PAC and WFA, there were no
significant changes in the CI values at various cell numbers. Thus, we concluded that
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increasing the cell numbers of H1299 and A549 did not alter the synergism between PAC
and WFA.

Table 2.1. Synergism Summary Table for PAC and WFA on H1299 Cells

Note: CI: Combination index, Dm: Median dose, m: shape of curve, r: goodness of fit

Table 2.2. Synergism Summary Table for PAC and WFA on A549 Cells

Note: CI: Combination index, Dm: Median dose, m: shape of curve, r: goodness of fit
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Fig 2.4. The combination of PAC and WFA significantly increased efficacy against colony
formation, proliferation and induction of apoptosis in NSCLC cells. Representative images
showing the colony formation assay in H1299 (a) and A549 (b) cells incubated with PAC and
WFA alone and in combination. In both cell lines, PAC and WFA alone dose-dependently inhibited
colony formation. However, the combination of PAC and WFA resulted in much greater inhibition
of colony formation than either drug alone. Cells were also treated with PAC and WFA for 12 h
(c), 24 h (d) and 48 h (e) and it was established that the synergism between PAC and WFA was
greatest at the 12 h incubation time point. (f) Annexin V/PI assay and (g)western blot analysis
depicted increased apoptosis induction. Moreover, the combination of PAC and WFA increased
the cleavage of PARP, caspase 3, increased Bax and decreased the expression of Bcl2.
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Fig 2.5. Increasing cell numbers did not alter the synergism of PAC and WFA against NSCLC
cells. H1299 and A549 cells were plated at indicated densities and incubated with PAC and WFA
alone, and in combination for 48 h. The efficacy and potency of PAC and WFA alone was greatly
diminished with increasing cell number in both H1299 (a-d) and A549 cells (e-h). However, the
combination of PAC and WFA synergistically inhibited the proliferation of both cell lines
regardless of the number of cells plated. Cell viability was measured by MTT assay, fractional
effects and synergism were assessed by combination index (CI <1) as per as per Chou et al.
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Effect of the PAC+WFA combination on migration and invasion of NSCLC cells.
Cell motility, migration, and invasion are all important steps that are critical for the
metastatic dissemination of NSCLC cells. Therefore, we investigated the effects of PAC
and WFA, alone and in combination, on these cellular events. To determine effects on cell
migration, we used the wound healing assay to assess the effects of PAC and WFA on cell
motility into cell-free areas. Representative images (Fig 2.6)were obtained using a light
microscope to monitor the wound areas between 0 and 24 h in order to determine the rate
of cell motility. Low doses of PAC and WFA alone, inhibited the motility of H1299 (Fig.
2.6a) and A549 (Fig. 2.6b) cells. Comparatively, H1299 cells displayed greater migratory
potential (>90% migration in 24 h) than A549 cells, thus the greatest effects on cellular
migration for PAC and WFA were observed with A549 cells than H1299 cells. In both cell
lines, at the tested concentrations, WFA displayed greater inhibitory effects on cell motility
than PAC. However, the combination of PAC and WFA resulted in much greater inhibition
of cellular motility than either PAC or WFA alone (<10%, **p<0.01). Furthermore, using
the trans-well migration and invasion assays, we showed that PAC or WFA alone
decreased migration and invasion compared to vehicle alone (Fig. 2.6c). As was observed
in the motility assay, the combination of PAC and WFA also significantly inhibited cell
migration than either drug used individually. In summary, the combination of PAC and
WFA not only synergistically inhibited cellular growth and proliferation, but also
significantly inhibited the migratory and metastatic capacities of H1299 and A549 cells.
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Fig 2.6. PAC and WFA inhibited NSCLC cell motility and migration. H1299 (a) and A549 (b)
cells were incubated with PAC (5 nM) and WFA (0.2 µM) alone, and in combination. Cell motility
was assessed by wound healing assay over 24 h. Pictures of wound areas were taken using a light
microscope and analysis by Wimasis software. (c) Invasion assay depicting the synergistic
inhibition of cellular trans-well migration in H1299 and A549 cells. Data are mean ±SD (*p<0.05).
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WFA targets PAC resistant TRA549 NSCLC cells in vitro and in vivo.
Previously published studies have reported that PAC treatment is associated with
the induction and development of chemoresistance in NSCLC cells [72-74]. For example,
Davi et al [75] have shown that PAC-resistance was developed in human NSCLC cell lines
by culturing these cells for >4 months in the presence of increasing concentrations of PAC
or cis-Pt. In the present study, we used PAC-resistant cells (TR-A549 cells) that were
developed as described previously (Fig. 2.7a) [69] and kindly provided as a gift by Dr.
Bruce Zetter (Harvard Medical School). Briefly, these TR-A549 cells were developed by
starting PAC treatments ½ PAC IC50 concentrations for 2 d followed by culturing the
surviving cells in drug-free media for 2 wks [70]. In subsequent cycles, the last PAC
concentration of the previous cycle was increased 2-fold until the development of
chemoresistance. The taxol-sensitive parental (TS-A549 cells) and taxol-resistant variants
(TR-A549 cells) were characterized for their drug response to PAC until we observed a 10fold change in IC50. In our studies, (Fig. 2.7b) we evaluated the sensitivity of both the drugsensitive and drug-resistant cells to PAC. Using the MTT and colony formation assays, we
found that the PAC-resistant cells (TR-A549 cells) displayed cross-resistance between
PAC and cis-Pt but remained sensitive to WFA (Fig. 2.7c-d). Consistent with previous
studies [75], we detected increased levels of mRNA and protein expression of MDR1 and
PDL-1 in the drug-resistant NSCLC cells (Fig. 2.7 e-f).
To evaluate the response of PAC-resistant TR-A549 cells to WFA, we explored
the antitumor effects of WFA on the growth and proliferation of TR-A549 cells both in
vitro and in vivo (Fig. 2.8). First, using in vitro assays, we demonstrated that both the
parental cells (TS A549) and drug-resistant variants (TR-A549) remained sensitive to WFA
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in vitro (Fig 2.8a). To determine the effects of WFA on PAC-resistant cells in vivo, we
established subcutaneous xenografts of PAC resistant cells in mice. WFA (10 mg/kg) was
administered intraperitoneally in 3 doses per week in athymic nude mice xenografted with
2 x 106 TR-A549 cells/mouse (Fig. 2.8b). In agreement with in vitro data, mice treated with
PAC (10 mg/kg divided into 3 doses a week) did not show any difference in tumor volume
compared to those treated with vehicle. However, WFA significantly and time-dependently
decreased the average tumor volumes of TRA549 xenografts when compared to vehicle
and PAC groups. Mechanistically, WFA inhibited the mRNA and protein expression of
MDR1 in TR A549 cells (Fig. 2.8c); however, modulation of PD-L1 with WFA remains to
be determined. Therefore, our data presented here show that in addition to synergizing the
effects of PAC, WFA targets both drug-sensitive and drug-resistant NSCLC cells. As such,
the ability of WFA to synergize the anticancer efficacy of PAC and cis-Pt in drug-sensitive
NSCLC cells, and target both drug-sensitive and drug-resistant NSCLC cells provides a
strong rationale for the development of a combination of PAC and WFA for the treatment
of NSCLC.
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Fig 2.7. PAC treatment induced MDR1-dependent chemoresistance in NSCLC cells. (a) A549
cells were incubated in media with or without sub-cytotoxic concentrations of PAC (>6 months).
(b) The cells incubated with PAC became resistant to PAC (TR-A549) while those incubated in
media without PAC remained sensitive to PAC (TS-A549). (c) Colony formation assay and (d)
MTT assay indicated decreased sensitivity of TR A549 cells to both PAC and CisPt but the cells
remained sensitive to WFA. (e-f) Confocal imaging, (f) RT-PCR and western blot analysis
indicated a significant increase in the expression of multi-resistant drug protein (MDR1).
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Fig 2.8. WFA alone inhibited the growth and proliferation of resistant PAC resistant NSCLC
cells. (a) MTT assay depicting the in vitro inhibition of cellular proliferation of TR A549 and TS
A549 (b) WFA significantly inhibited the growth of TR A549 (2.5 x106 cells/mouse) tumor
xenografts in athymic nude mice. (c) RT PCR and western blot analysis indicated dose-dependent
inhibition of the expression MDR1 in TR A549 after incubation with WFA for 48 h. (d-e)
AnnexinV/PI assay indicated dose-dependent induction of apoptosis in TR A549 cells after
incubation with WFA (0-2µM) for 24 h. (f) Western blot analysis confirmed the induction of
apoptosis as indicated by the increased cleavage of PARP and caspase 3, increased expression of
Bax, p21, phosphor-H3 while inhibiting the expression of Bcl2 and cyclin E2.
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DISCUSSION
Today, taxane-platinum chemotherapeutic drug combinations remain the standard
of care as first-line regimens for all sub-types of advanced NSCLC with no targetable
driver genetic mutations. Cisplatin (cis-Pt) alongside paclitaxel (PAC) although highly
toxic, is the most widely used and most efficacious two-drug combination for the treatment
of advanced NSCLC [13, 16, 48]. However, due to drug resistance, tumor relapse, and
metastasis, the response rate has plateaued at 20 - 30% and the survival efficacy is currently
about 10-14 months [48, 49]. Moreover, despite advancements in molecularly targeted
drugs and immunotherapies, chemoresistance and metastasis remain almost universal in
NSCLC [46]. In addition, the currently used chemotherapeutic drugs are highly toxic,
sometimes causing severe, irreversible and life-threatening toxicities in patients. Thus, the
systemic treatment of advanced NSCLC remains a major therapeutic challenge, and there
is a significant unmet clinical need to develop safe and efficacious alternative therapies for
advanced NSCLC.
In the present study, we investigated the efficacy of various combinations of WFA
and PAC synergistic against the growth and proliferation of human NSCLC cells. WFA, a
plant-derived steroidal-lactone is the most prominent member of a large group of naturally
occurring 28-carbon compounds called withanolides. Previously, multiple preclinical
studies have extensively examined the anticancer effects of WFA on different cancer types
[22]. In the current study, we demostrate that WFA is highly active against the proliferation
of the human NSCLC cell lines, H1299 and A549. Mechanistically, at cytotoxic
concentrations, WFA increased the generation of ROS, an indicator that WFA induces cells
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to undergo oxidative stress, and subsequently apoptosis. The generation of ROS was
comfirmed by using a H2O2 as a positive control and was inhibited in the presence of the
ROS quencher, NAC. Interestingly, whereas we observed that ROS production was related
to the cytotoxicity of WFA, only thiol containing ROS quenchers such as NAC and DTT
inhibited the antitumor effects of WFA. Understandably, this phenomenon indicated that
the generation of ROS was secondary to the cytotoxic antitumor activities of WFA.
Therefore, although not fully investigated in present study, it appears that the molecular
mechanism of action of WFA involve thiol binding as one of the more critical steps.
To establish the in vitro potency and efficacy, we have demonstrated that WFA as
a single agent was active against both H1299 and A549 cells. However, since it is highly
unlikely that NSCLC would be treated with monotherapy, the more attractive approach
was to investigate the synergistic combination of WFA with standard chemotherapeutic
drugs [41, 43, 76]. Along these line, we explored the potential for WFA to synergize the
effects of PAC and/or cis-Pt against the proliferation of human NSCLC cells. This strategy
was particularly exciting for the case of NSCLC since the clinical efficacy with the current
treatments seems to have reached a maximum with disappointingly low survival outcomes
[43]. Based on the data presented, as individual drugs, PAC, a tubulin inhibitor showed the
greatest potency (lowest IC50) against both H1299 and A549 human NSCLC cell lines.
These findings are supported by several previously published studies [59, 60] and strongly
suggest that PAC remains the most important component of the PAC+cis-Pt combination
in NSCLC treatment. As such, we took PAC to represent the standard of care and then
demonstrated that its combination with WFA resulted in much greater efficacy than when
combined with cis-Pt, the standard of care.
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Chou et al [71] have developed a robust method for the analysis of the synergism
for two or more drug combinations using the median-effect equations. Several studies have
applied this method to investigate the synergistic effects of anticancer drugs against breast
[77], lung, pancreatic [76] and ovarian [41] cancers. Similarly, we used these median-effect
equations as described previously to determine whether PAC and WFA were synergistic.
In our studies, we demonstrated that WFA dramatically increased the efficacy and potency
of both PAC and cis-Pt in a synergistic manner (CI<1). However, the synergistic effects
observed with PAC and WFA were much greater than those for PAC and cis-Pt or WFA
and cis-Pt, respectively. Interestingly, in the synergistic combinations, the observed
dramatic decreases in the IC50 values were much greater for PAC than were for WFA,
indicating that the greatest contribution towards synergism was from WFA in either cell
lines. These observations were strongly supported by the findings from previous studies
[41, 42] in which WFA has been previously reported to synergize the effects of standard
chemotherapeutic drugs. Therefore, based on the current findings, we hypothesize that
using WFA alongside PAC in NSCLC would significantly enhance clinical efficacy while
dramatically decreasing the potential for toxicity in patients. In the clinic, oncologists
administer chemotherapeutic drugs following complex dosing schedules to prevent
overlapping toxicities. Liu et al have shown that the synergism of anticancer drugs can be
enhanced by altering the sequence, concentration, schedule and duration of drug exposure
[78-80]. To this effect, we investigated whether the synergism observed between PAC and
WFA could be increased by altering sequence and schedule of treatment. Our findings
showed that the synergistic effects of PAC and WFA were not scheduled dependent but we
demonstrated that preincubation of H1299 and A549 cells with WFA for 2 h dramatically
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enhanced the antiproliferative efficacy of the combination of PAC and WFA. Thus, it could
be concluded that WFA had a chemosensitizing effect on PAC against NSCLC cells as has
been repoted in previous studies conducted with other cancer cell types [22].
Chemoresistance and metastasis remain the primary causes of death in advanced
NSCLC with no clinically effective approved drugs [81]. At the molecular level, intrinsic
and acquired resistance mechanisms in tumor cells contribute to >80% of treatment failure
in NSCLC. Furthermore, accumulating evidence from previous studies has shown that the
development of chemoresistance is simultaneously induced for multiple antitumor agents
following the treatment with only one agent. For example, studies [16, 70, 75] have shown
that chronic incubation of NSCLC cells with PAC treatment induces chemoresistance to
cis-Pt and other chemotherapeutic agents. At the molecular level, PAC induces cellular
mechanisms such as EMT in NSCLC cells that trigger the development of chemoresistance
and metastasis. In the present study, we used a previously developed PAC resistant (TRA549) cell line that expressed high levels of MDR1 indicating that chemoresistance was
mediated by increased drug-efflux from cells. Also, we observed high levels of PDL-1
expression in TR-A549 cells which strongly suggested a link between the simultaneous
development of drug resistance and immune evasion in NSCLC [82]. Using this TR-A549
cell line, we demonstrated that WFA was active against both drug-sensitive and drugresistant NSCLC tumor cells. Since WFA was active against this MDR-1 overexpressing
TR-A549 cell line, it appears that WFA is not a substrate for MDR-1 and has the potential
to inhibit MDR-1 dependent drug resistance in NSCLC. Furthermore, the TR-A549 cells
displayed decreased E-cadherin expression, a molecular indicator that PAC induced an
EMT phenotype in NSCLC. In a recent study [83], we have shown that WFA inhibits EMT
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in NSCLC cells, and we therefore strongly hypothesize that the use of PAC and WFA can
prevent the emergence of drug resistance and metastasis in NSCLC. Together, these novel
findings strongly support our rationale for combining PAC with WFA, and further suggest
that this strategy has an additional benefit of the ability to prevent the emergence or target
drug resistance and metastasis in NSCLC.
In conclusion, we have investigated and demonstrated the therapeutic potential of
WFA alone and in combination with PAC against human NSCLC cells. Using in vitro
antiproliferative assays, we have shown that PAC and WFA are highly synergistic against
H1299 (large cell carcinoma) and A549 (adenocarcinoma) cells. Moreover, the PAC and
WFA combinations were more efficacious than PAC and cis-Pt or WFA and cis-Pt,
respectively, against both H1299 and A549 human NSCLC cells. In addition, WFA was
active against the proliferation of the drug-resistant (TR-A549) cells and decreased the
expression of MDR-1 in these cells. Together these findings provide a strong rationale for
further development of the PAC and WFA combination to advance a new therapeutic
alternative for the treatment of advanced NSCLC.
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CHAPTER THREE
WITHAFERIN A INHIBITS EPITHELIAL TO MESENCHYMAL TRANSITION IN
NON-SMALL CELL LUNG CANCER CELLS
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths worldwide [10] and in the
United States [44]. Non-small cell lung cancer (NSCLC) which accounts for about 85-90%
of all lung cancer cases has an overall five-year survival rate of 15-17% [84, 85]. Despite
recent advancements in early detection methods [81, 86], surgical techniques, targeted and
immunotherapies [87], the overall survival from NSCLC has only minimally improved.
This poor prognosis is explained in part because about 50-70% of all NSCLC patients are
diagnosed when the disease is at an advanced stage and are not curable regardless of
treatment approach [81]. Furthermore, the rate of tumor recurrence among NSCLC patients
who undergo surgical resection is about 30-70%, most of whom eventually succumb to
metastasis [15, 45].
Tumor cell migration, invasion, and metastasis are the primary causes of treatment
failure and death among NSCLC patients [84, 88]. Unlike cellular proliferation, the
therapeutic targeting of metastasis is difficult with no clinically-effective drugs. Metastatic
processes are complex, and the underlying mechanisms are still poorly understood. because
they utilize an interplay of cell adhesion, motility, and survival pathways [89].
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Recently, several clinical and preclinical studies indicate that epithelial-to-mesenchymal
transition (EMT) plays is a crucial role in the metastatic process of NSCLC cells [90, 91].
EMT is a complex but dynamic biochemical process of cellular reprogramming where
epithelial cells undergo extensive molecular and morphological changes to acquire a
mesenchymal phenotype. Normally, EMT critical during embryogenesis, angiogenesis and
wound healing but tumor cells invoke EMT to increase their motility, migratory, and
invasive capacities [92, 93]. The importance of EMT in metastasis has prompted the
evaluation of small molecule inhibitors of EMT as potential drugs against metastasis in
NSCLC [89].
Withaferin A (WFA) is a biologically active steroidal-lactone that was first isolated
from the extracts of the Indian Ayurvedic medicinal plant, Withania somnifera [24].
Previous studies have demonstrated multiple pharmacological effects of WFA including
antitumor, anti-inflammatory, pro-apoptotic, immunomodulatory, hepatoprotective,
anabolic, antiangiogenic, and anti-fibrotic activities. Despite these multiple effects, WFA
has attracted significant preclinical testing mainly for its antitumor activities [22]. Indeed,
WFA has been shown to be cytotoxic against lung [40, 62-64], cervical [66], prostate [39,
94], breast [31, 35, 37], ovarian [41-43], colon [95], B-cell lymphoma [68], and pancreatic
[76] cancers in the preclinical setting. More importantly, in addition to cytotoxicity, WFA
displays remarkable anti-invasive and anti-metastatic activities [22, 31, 96]. Although the
molecular mechanisms underlying the activity of WFA are not fully understood, its antimetastatic effects have been attributed in part to its inhibition of EMT in tumor cells.
Previously, anti-EMT properties of WFA have been demonstrated on breast, ovarian,
and mammalian epithelial cells [22]. In the present study, we examined the effects of WFA
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on migration, invasion, and EMT induction in A549 and H1299 cells. Here, we show that
the cytokines TGF1 and TNF cooperate to induce EMT, increase migration and invasion
of these tumor cells. Importantly, we demonstrated that sub-cytotoxic doses of WFA
suppressed TGF/TNF-induced EMT, cell adhesion, migration, invasion, and motility.
Mechanistically, WFA inhibited TGF1-dependent Smad2/3-signaling and TNFdependent NFκB signaling. Together, this data provides additional evidence on role WFA
in regulating EMT in tumor cells and further demonstrates the therapeutic potential of
WFA for the treatment of metastatic NSCLC.
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MATERIALS AND METHODS
Reagents, chemicals, and supplies.
WFA (>96% pure) was generously provided as a gift sample by 3P Biotechnologies Inc.,
(Louisville, KY, USA). A stock solution of WFA (5 mM) was prepared in dimethyl
sulfoxide (DMSO) and stored in aliquots at -20°C until use. MTT (3-[4,5-dimethylthiazol2-yl]-2,5-diphenyltetrazolium bromide) was purchased from Alfa Aesar (Ward Hill, MA,
USA). RIPA cell lysis buffer, BCA protein assay kit, PVDF membranes, phosphatebuffered- saline (PBS), ECL chemiluminescence reagent, and Bolt 4-12% Bis-Tris
phosphate gels were purchased from ThermoFisher (Rockford, IL, USA). Dulbecco's
modified Eagle’s medium (DMEM), penicillin and streptomycin were purchased from Life
Technologies (Gibco, Grand Islands, NY, USA). Fetal bovine serum (FBS) was purchased
from VWR, Seradigm Life science (Radnor, PA, USA). The human recombinant TGFβ-1
(#8915) and TNFα (#8902) were purchased from Cell Signaling Technology (Danvers,
MA, USA) and prepared as 50 µg/mL stock solutions in sterile 20 mM citrate, pH 3.0 and
sterile PBS, respectively. The stock solution was stored in aliquots at -80°C and diluted in
serum-free DMEM media before use.
Antibodies.
Primary antibodies against Smad2/3, phospho-Smad2/3, Smad 2, Smad3, phospho-Smad2,
phospho-Smad3, Smad4, Smad7, Snail, Slug, E-cadherin, ZEB1, N-cadherin, Vimentin,
NFκB, pNFκB, IκB, phospho-IκB, IKKα, IKKβ, phospho-IKKα/β, and were purchased
from Cell Signaling Technology (Danvers, MA). The primary antibodies against β-actin
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were purchased from Sigma Chemical Co. (St. Louis, MO). A detailed list of all antibodies
used is presented in Supplementary Table 1.
Cell culture conditions.
The human NSCLC cell lines, A549, and H1299 were maintained in DMEM media
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotics (100 U/mL
penicillin and 100 µg/mL streptomycin), at 37°C with 5% CO2 in a humidified incubator.
Culture media was replaced every 48h and the cells were passaged at 80% confluence,
for less than 20 cycles.
Cell viability assay.
Cell viability was determined by MTT assay as described previously. Briefly, cells were
seeded in 96-well plates (3 x 103 cells/well) and preincubated for 24 h before treatments.
DMEM was replaced with fresh media containing various concentrations [0-5 µM] of
WFA and incubated for an additional 24, 48, and 72 h. The cells were then incubated with
the 0.5 mg/mL MTT reagent for 3 h and formazan crystals formed were solubilized using
200 µL of DMSO. The absorbance of the resulting solution was measured at 570 nm. Data
were expressed as mean  SD of four or more separate experiments.
Cell adhesion assay.
Cells were serum starved for 12 h and then incubated with WFA in the presence or absence
of TGFβ1 or TNFα in serum-free media for 1 h. The cells were then seeded in Matrigel (50
μg/mL) pre-coated 96-well plates (5 x104 cells/ well) and incubated for 2 h to allow
attachment. Non-adherent cells were washed away using pre-warmed sterile PBS, and then
fresh DMEM media (10% FBS) was added to each well. Cultures were incubated for an
additional 4 h, and then cell viability was measured using MTT assay.
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Colony formation assay.
Cells were incubated with or without WFA for 24 h, trypsinized and then seeded in 6well plates at 200 cells/well density. Fresh DMEM media was added and changed every
48 h for a total of 7 d. The colonies formed were fixed using methanol/acetic acid
solution (3:1), and stained with 0.2% crystal violet. The number of colonies formed was
recorded using a high-resolution digital camera and counted using a microscope in five
random fields.
Wound healing assay.
The wound-healing assay was performed using the 2-well inserts from ibidi® (Munich,
Germany). Briefly, cells (1 x104 cells/well) were seeded into the 2-well inserts and
incubated for 24 h to allow cell attachment. The cell-free gaps (wounds) were created by
removing the culture inserts. Floating cells and cellular debris were washed off using sterile
PBS, and media was replaced with fresh media containing WFA in the presence or absence
of TGFβ1 and TNFα. The distance migrated by cells in each cell-free gap was monitored
by light microscopy at 0, 12, and 24 h. At each time point, 3 random microphotographs of
the wound area were taken. The percent migration was quantified using Wimasis Image
Analysis software (WimScratch, Cordoba, Spain).
Transwell migration and invasion assays.
Migration and invasion assays were performed using uncoated and Matrigel-coated 8 µm
pore transwell chambers (BD Bioscience, San Jose, CA), respectively. Cells (4 x 104
cells/well) were suspended in serum-free DMEM media and seeded into the upper
compartments of transwells. DMEM media containing 10% FBS was added to the lower
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chamber as a chemoattractant to cause cell migration from the upper chamber to the lower
chamber of the transwells. Cell migration was allowed to occur for 24 h, and the migrated
cells were fixed using 4% paraformaldehyde solution. Cells were permeabilized using
100% methanol and then stained using 0.2% toluidine blue. Migrated cells in five random
fields were examined using a microscope and microphotographs taken using a highresolution digital camera.
Western blot analysis.
Following incubation with indicated treatments, cells were harvested by trypsinization and
washed twice with ice-cold PBS. Whole-cell protein lysates were prepared by suspending
cell pellets in RIPA cell lysis buffer at 4C. Protein concentration for the cellular lysate
was determined by BCA method and protein samples (20 µg) were resolved by SDS-PAGE
and then transferred to PVDF membranes. The expression of specific proteins was
determined by probing the PVDF membranes with specific primary monoclonal
antibodies, followed by the respective HRP-conjugated secondary antibodies. The levels
of each protein were determined by visualizing protein bands on blots using ECL detection
reagents (Thermo Scientific, Rockford, IL). The relative density of each blot was quantified
using the ImageJ software (NIH, Bethesda, MD). β-actin (Sigma-Aldrich, St. Louis, MO)
was used as protein loading controls.
Electrophoretic Mobility Shift Assay (EMSA).
To determine the effect of WFA on the binding of NFκB to nucleic acids, the
electrophoretic mobility shift assay (EMSA) was performed. Briefly, cells were incubated
with or without WFA for 24 h, and then was NFκB stimulated using 5 ng/mL TNFα for 30
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min. Cytosolic and nuclear cell extracts were prepared using standard protocols. A total of
30 µg nuclear protein was incubated with 32P end-labeled double-stranded NFκB, and the
DNA–protein complex formed were separated from free oligonucleotide on 6% native
polyacrylamide gels. The radioactive bands were visualized by a Packard InstantImager.
Immunofluorescence staining.
Cells were seeded in 8-well chamber slides and cultured up to 60-70% confluency. After
24 h serum starvation, cells were incubated with TGF1 or TNF in the presence or
absence of WFA for 24 h. Then, cells were fixed using 4% paraformaldehyde and
permeabilized using 0.25% Triton X-100 in PBS. The fixed cells were blocked using 1%
BSA for 1 h at 23°C and then probed with specific primary antibodies at 4°C overnight.
The primary antibodies were then probed with fluorescent-tagged secondary monoclonal
antibodies diluted in 1% BSA in PBS for 2 h at 23°C. F-actin was stained using green or
red fluorescent phalloidin while the nuclei were stained blue using DAPI.
qRT-PCR analysis.
Total RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, CA) as
per the manufacturer’s instructions. The relative expression of E-cadherin, vimentin,
Snail, and fibronectin mRNA levels were determined by qRT-PCR and normalized to
the expression of GAPDH. qRT-PCR was performed using Power SYBR Green RNA to
CT 1-Step Kit. The primers used in the qRT-PCR assay are listed in table 1 in the
supplementary information. Relative mRNA levels were determined by calculating the
fold change for each sample using the 2−ΔΔCt relative quantification method.
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Statistical analysis.
Statistical analysis was performed using Graph Pad Prism 7.0 software. Data were
presented as means ± SD of at least 3 separate experiments. First, One-way analysis of
variance (ANOVA) was used to determine variations among experimental and control
groups. Comparisons of individual experimental and control group means were done using
the students' t-test, and p-values <0.05 were considered statistically significant.
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RESULTS
WFA inhibits the growth and proliferation of A549 and H1299 cells.
First, we determined the cytotoxic effects of WFA against the two human NSCLC
cell lines H1299 and A549, which are known to be highly and moderately metastatic,
respectively. Incubation of cells with WFA caused dose- and time-dependent cytotoxicity
to both A549 and H1299 cells. Phase-contrast images (Fig. 3.1b) were obtained after 48 h
of cell culture in the presence of WFA. The images revealed significant dose-dependent
changes in cellular morphology of both A549 and H1299 cells, that were indicative of
decreased cell viability and/or increased cell death. To quantitatively determine the
cytotoxic effects of WFA on A549 and H1299 cells, we used the MTT assay to measure
cell viability. By considering the vehicle-treated cells as 100% viable, our data (Fig. 3.1c)
shows that WFA dose-dependently decreased the viability of both A549 and H1299 cells.
The anti-proliferative effects of WFA on NSCLC cells were both time- and concentrationdependent (Fig. 3.1d-e).
Next, to validate the MTT data, we assessed the effects of WFA on the replicative
ability of A549 and H1299 cells by conducting the colony formation assay. Representative
images (Fig. 3.1f) of A549 and H1299 colonies stained using 0.5% crystal violet in
methanol. In support of our MTT assay data, WFA significantly inhibited the ability of
cells to form colonies. Together, this data demonstrates the remarkable cytotoxic effects
of WFA against A549 and H1299 human NSCLC cells in vitro. Overall, we found the
highly invasive H1299 cells to be more sensitive to WFA than the moderately invasive
A549 cells.
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Fig 3.1. WFA suppressed the growth and proliferation of A549 and H1299 cells. (a)
Chemical structure of WFA. (b) Phase-contrast images (4X magnification) showing the
cellular morphology following incubation with WFA for 48 h. (c) Dose-dependent
antiproliferative activity of WFA against A549 and H1299 cells after 72 h incubation.
Time- and concentration-dependent inhibitory effects of WFA on the growth and
proliferation of A549 (d) and (e) H1299 cells. (f) Representative images of colony
formation assay depicting a dose-dependent inhibitory effect of WFA on A549 and H1299
cells. Cell viability was measured using MTT assay while the number of colonies formed
were counted using a microscope and data are presented as mean ± SD of 3 technical
replicates. *p<0.05, **p<0.01.
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WFA inhibits cell adhesion, migration, and invasion of A549 and H1299 cells
Increased migratory and invasive behaviors of tumor cells are known to be
indicative of higher metastatic potential in NSCLC tumors. Therefore, to test whether
WFA inhibited the metastatic potential of A549 and H1299 cells, we conducted the cell
adhesion, migration, and invasion assays. We used the cell adhesion assay to determine
the potential of A549 and H1299 to attach to an extracellular matrix in the presence of
WFA. The vehicle-treated cells (Fig. 3.2a) were considered to have 100% adhesion to
Matrigel, while WFA treated cells displayed dose-dependent in cell adhesion for both
A549 and H1299 cells. Next, to examine the effects of WFA on cell motility, we
performed the wound healing assay for both A549 and H1299 cells. We observed (Fig.
3.2b) that 0.5 µM WFA significantly suppressed cell motility of both A549 and H1299
cells. In untreated (vehicle-treated) cells, >95% of the wound areas were covered by cells
indicating higher cell motility. However, in the presence of WFA, we observed only 2040% motility of these cells (*p<0.05).
Furthermore, we also determined the effect of WFA on transwell migration and
invasion using 8 µm-pore transwell chambers coated with or without Matrigel. The number
of migrated cells were counted in five random fields under a microscope and presented as
mean ± SD. Representative microphotographs of migrated and invaded cells show that
WFA significantly suppressed the migration and invasion of A549 and H1299 cells (Fig
3.2c).
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Figure 3.2. WFA inhibited cell adhesion, motility, migration, and invasion of A549 and
H1299 cells. (a) Cell adhesion assay depicting the dose-dependent inhibition of the
adhesion of A549 and H1299 cells. (b) Wound healing assay showing the inhibitory effect
of WFA on the motility of A549 and H1299 cells. (c) Representative images showing the
effect of WFA on transwell migration and invasion of A549 and H1299 cells following
incubation with WFA. Data are mean ± SD, *p<0.05.
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WFA inhibited experimental EMT induction in A549 and H1299 cells.
The loss of the epithelial marker E-cadherin and an increase in the expression of
N-cadherin (also known as the cadherin switch) is the hallmark of EMT induction in
tumor cells. Previously, TGFβ1 and TNFα either individually or in combination have
been used to induce experimental EMT in various tumor cell types including NSCLC.
In the present study, we assessed whether WFA could inhibit experimentally induced
EMT in A549 and H1299 cells. First, we induced EMT in A549 and H1299 cells by
culturing cells in serum-free media containing TGF1 (5 ng/mL) and TNF (25 ng/mL)
alone or in combination. Data presented (Fig. 3.3a) shows the western blot analysis of
whole-cell lysates prepared from A549 and H1299 cells following EMT induction. In
the vehicle-treated cells, the highly invasive H1299 cells did not express E-cadherin but
A549 cells expressed significant levels of E-cadherin. However, incubation of A549
cells with TGFβ1 and TNFα either alone or in combination resulted in a significant
decrease in the expression of E-cadherin in A549 cells while upregulating N-cadherin.
This finding indicated that culturing A549 cells in the presence of these cytokines
resulted in EMT induction. Using qRT-PCR analysis (Fig. 3.3b), it was found that the
repression of E-Cadherin expression was associated with decreased levels of mRNA in
A549 cells. On the other hand, the expression levels of the EMT-related proteins such
as vimentin, Snail, fibronectin, and claudin-1 were all significantly increased after
incubation with the cytokines. Interestingly, the expression of Snail, a known EMT
transcription factor was significantly increased by TGFβ1 alone or in the combination
of TGFβ1 and TNFα but not TNFα. Also, only TGFβ1 significantly increased the
expression of vimentin as indicated by western blot (Fig. 3.3a) and qRT-PCR (Fig.3.3b).
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Fig 3.3. WFA inhibited experimental EMT induction in A549 and H1299 cells. Cells
were left untreated or pretreated with 0.5 µM WFA for 12 h and then stimulated with
TGFβ1 or TNFα alone and in combination in serum free media. EMT induction was
assessed by western blot analysis, qRT-PCR, and immunofluorescence staining. (a)
Western blot analysis depicting the expression levels the epithelial marker E-cadherin, and
the EMT-related proteins N-cadherin, Snail, vimentin, and fibronectin (b) qRT-PCR
depicting the relative mRNA expression. Fold change was calculated using the ΔΔCт
method and GAPDH was used as normalizing gene. (c) Phase-contrast images (4x
magnification) and confocal images showing changes in cellular morphology and the
expression of E-cadherin and vimentin in A549 cells following incubation with a
combination of TGFβ1 and TNFα in the presence or absence of 0.5 µM WFA. (*p<0.05
vs. untreated).
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When cells were pre-incubated with 0.5 µM WFA prior to EMT induction, the observed
repression of E-cadherin or the upregulation of vimentin, Snail, fibronectin, and claudin1 were inhibited. This inhibitory effect of WFA was confirmed using both western bl ot
analysis and qRT-PCR analysis. To further validate these data, we performed
immunofluorescence staining to determine the expression of E-cadherin and vimentin
in A549 cells following EMT induction. Phase contrast and confocal images (Fig 3.3c)
show the morphological changes, downregulation of E-cadherin, and the upregulation
of vimentin as indicators of EMT induction in A549 cells. There was evidence of loss
of cell to cell contact, and the cells became more elongated. However, in support of data
obtained by western blot and qRT-PCR analysis, WFA significantly inhibited EMT
induction in A549 cells. Further, we assessed the effects of WFA motility of both A549
and H1299 cells in the presence of TGF1 and TNF. As indicated (Fig. 3.4), TGFβ1
and TNFα significantly increased the motility which was suppressed in the presence of
WFA.
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Fig 3.4. WFA suppressed TGFβ1/TNFα-induced motility of A549 and H1299 cells.
Wound healing assay was used to measure the motility of the cells in the presence 0.5 µM
WFA and a combination of TGFβ1 (5 ng/mL) or TNFα (25 ng/mL). The figure shows that
TGFβ1/TNFα significantly enhanced the motility of A549 (a), and H1299 (b) cells. Data
are presented as percent migration (mean ± SD) by considering wound area at time 0 h as
100%. (*p<0.05) higher motility compared with vehicle-treated cells.
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WFA inhibited TGF1-dependent Smad2/3 signaling in A549 and H1299 cells
TGFβ1-induced EMT in tumor cells has been shown to occur mainly through the
activation of Smad-dependent signaling pathways. Therefore, to assess whether WFA
affected TGFβ-induced Smad2/3 activation, cells were incubated with WFA at indicated
concentrations and then stimulated with TGFβ1 (5ng/mL). The phosphorylation of
Smad2/3 was assessed by immunofluorescence staining and western blot analysis.
Confocal images (40x magnification) of A549 cells (Fig. 3.5a) shows probed for pSmad2/3 (green), F-actin (red) and nuclei (blue). These images show that TGF1
increased the levels of p-Smad2/3 and its nuclear localization when compared to vehicletreated cells. However, pre-incubation of cells with WFA prior to TGFβ1stimulation,
the phosphorylation and nuclear translocation of Smad2/3 was inhibited.
To validate the confocal data, we performed western blot analysis on whole cell,
nuclear, and cytoplasmic lysates prepared from A549 and H1299 cells. As shown in
(Fig.3.5b), we observed that WFA dose-dependently suppressed Smad2 and Smad3
phosphorylation and thus prevented their nuclear translocation. Moreover, it appears
that WFA also decreased the levels of total Smad3 in a dose-dependent manner. Overall,
the data presented here show that WFA inhibited TGFβ1-induced EMT at least in part
via its regulation of Smad-dependent mechanisms.
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Fig 3.5. WFA inhibited TGFβ1-dependent activation of Smad2/3 in A549 and H1299
cells. (a) Confocal images of A549 NSCLC cells depicting the inhibitory effect of WFA
(1.0 µM) on TGFβ1 (5 ng/mL)-induced Smad2/3 phosphorylation in A549 cells. (b)
Western blot analysis of whole cell lysates depicting the dose-dependent inhibitory effect
of WFA on the Smad2/3 signaling pathway (c) Western blot analysis of cytosolic and
nuclear fractions from A549 cells showed decreased Smad2/3 phosphorylation and nuclear
translocation in the presence of WFA. GAPDH was used the total protein loading control.
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WFA inhibited TNF-induced NFB signaling in A549 and H1299 cells.
TNF stimulates aberrant NF-κB signaling pathways in tumor cells to regulate
motility, migration, invasion, and chemo-resistance [97]. In the present study, we
investigated whether WFA inhibited TNF-induced activation of NFB in H1299 and
A549 cells. As shown in Figure 6, TNF stimulated the NF-B signaling pathway by
inducing the phosphorylation and nuclear translocation of NF-B (P65). As assessed by
immunofluorescence staining (Fig. 3.6a), cells stimulated with TNF had higher levels
of p-NF-B than vehicle-treated controls. However, pre-incubation of cells with WFA
significantly decreased the phosphorylation of NFB. Western blot analysis (Fig. 3.6bc) of the whole-cell and cytosolic lysates indicates that TNF alone increased the
phosphorylation of IBα (p-IBα) and NFB (p-NF-B). The phosphorylation of IκB
resulted in increased degradation of IB and the nuclear translocation of NF-κB (P65).
However, WFA suppressed the TNF-dependent phosphorylation of NF-B (P65) and
IBα, the degradation of IBα and nuclear translocation of NF-κB (P65). Interestingly,
the total levels of NF-κB (P65) were not significantly affected by WFA indicating that
WFA inhibited NFκB signaling by regulation phosphorylation. By measuring the levels
of total and phosphorylated IKKα/β, we found that WFA inhibited NF-κB(P65) by
regulating the activity of IKKα/β. Furthermore, we also investigated the effect of WFA
on the transcriptional activity of NFκB (P65) using the electrophoretic mobility shift
assay (EMSA). Our data (Fig. 3.6e) shows WFA decreased the binding of NFκB (p65)
on to DNA in both A549 and H1299 cells. Overall, we demonstrate that WFA
remarkably inhibited TNF-induced degradation of IB resulting in inhibition of the
activation of NF-B without affecting total NFκB levels in A549 and H1299 cells.
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Fig 3.6. Inhibition of TNFα-induced NFκB activation in human NSCLC cells. (a)
Confocal images (40x magnification) showing the levels of p-NF-κB. (b) Western blot
analysis depicting levels of p-NFκB, total NF-kB, p-IκB, and total IκB in whole cell lysates
following stimulation with TNFα (25 ng/mL (c) Western blot analysis of nuclear and
cytosolic cell extracts depicting levels of NFκB, p-NFκB, IκBα, and p-IκBα following
stimulation with TNFα.
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DISCUSSION
Despite the recent advances in the treatment of NSCLC such as targeted therapies
and immunotherapies, invasion and metastasis remain a major therapeutic challenge in
NSCLC [81]. Recently, it has become clear that EMT plays a crucial role in the metastasis
of NSCLC tumors and therefore has become an attractive drug target [90]. It has been
shown that EMT induction causes tumor cells to become more migratory, invasive, and
metastatic [92]. Additionally, EMT stimulates tumor cells to acquire stem cell-like
properties and increases resistance to standard chemotherapeutic drugs [98]. Therefore, the
importance of EMT during metastasis and in drug resistance of tumor cells has prompted
the search for compounds that inhibit EMT in tumor cells as potential drugs for metastatic
NSCLC [99]. Based on this hypothesis, we and others [31, 43, 96] have examined the
effects of WFA on experimentally induced EMT to demonstrate its potential antimetastatic properties.
WFA is a member of the withanolides, a large group of naturally occurring
28carbon-containing compounds [19]. The basic chemical structure of withanolides is
composed of a steroidal framework attached to a lactone ring, and are also referred to as
‘steroidal-lactones’ [20]. In WFA (Figure 1A), there are five functional groups including;
an unsaturated ketone ring, 2 hydroxyl groups, an epoxide ring, a 6-carbon lactone ring,
and an unsaturated carbonyl group [27, 28]. It has been shown that these five functional
groups enable WFA to interact with several molecular targets and account for the diverse
biological activities of WFA including its anti-cancer properties [22]. Multiple lines of
experimental evidence from in vitro and in vivo studies show that WFA is a highly
efficacious anti-tumor molecule that displays both cytotoxic activities against multiple
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cancer cells [37, 64, 100]. Recently, the effects of WFA on tumor cell migration, invasion,
and metastasis [22]have gained a lot of attention and have stimulated interest in
investigating the anti-metastatic properties of WFA. Importantly, unlike common cytotoxic
chemotherapeutic drugs that have been shown to induce EMT [101], WFA, on the other
hand, suppresses EMT [31, 43, 96, 102] and therefore has the capability to prevent
metastasis and drug resistance in multiple cancers.
Earlier studies have shown that sub-cytotoxic doses inhibit EMT induction in the
breast, ovarian, and mammalian epithelial cells [96, 103]. In fact, detailed molecular
evidence showed that WFA binds to and causes the degradation of the EMT-related
intermediate filament protein, vimentin [31]. Similarly, our study highlights the role of
WFA in regulating EMT and metastasis in tumor cells. Initially, we determined the
cytotoxicity of WFA on anchorage-dependent growth and proliferation of A549 and H1299
cells. As reported elsewhere [64], our findings show remarkable cytotoxicity of WFA on
the anchorage-dependent proliferation of NSCLC cells. Notably, the highly invasive
H1299 cells were more sensitive to WFA than the moderately invasive A549 cells. This
finding suggests and strengthens the hypothesis that WFA is likely more potent against the
highly metastatic tumors which are incidentally found in the majority of NSCLC patients.
During the EMT process, tumor cells lose cell to cell contacts, become more
invasive and resistant to cytotoxic drugs [104]. At the molecular level, it is reported that
the loss of the epithelial marker E-cadherin coupled with an increase in mesenchymal
markers such as vimentin and N-cadherin are the hallmarks of EMT [90]. Furthermore,
EMT pathways are regulated by various extracellular signals including cytokines in the
tumor microenvironment such as TGF1 and TNFα [104, 105]. Experimentally, EMT
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induction in tumor cells has been modeled by culturing cells in serum-free media
containing TGFβ1 and/or TNFα [92]. Using this model, we successfully induced EMT in
A549 and H1299 cells using TGF1 and TNF. In agreement with previous studies [106],
our findings data shows synergistic cooperation between TGF1 and TNF on E-cadherin
repression. More importantly, pre-incubation of cells with WFA prior to EMT induction
prevented the loss of E-cadherin or the upregulation of N-cadherin. Together with previous
data [31, 96, 107], our study demonstrates that WFA is a powerful suppressor of EMT
induction and further highlights the anti-metastatic effects of WFA.
The molecular mechanisms underlying EMT are complex but the transcription
factor Snail has been shown to be a key regulator of EMT induction in NSCLC cells [105].
Specifically, Snail binds to DNA and causes the repression of E-cadherin expression while
upregulating EMT-related proteins such as vimentin, N-cadherin, and fibronectin [92, 98,
105]. Snail expression and function are regulated by extracellular signals such as TGFβ1
[90, 92] and TNFα [106] via Smad- and NF-κB-dependent signaling pathways,
respectively. Moreover, simultaneous activation of these two pathways synergistically
increases the expression Snail in A549 cells [106, 108, 109]. In agreement with this
observation, we demonstrated that a combination of TGF1 and TNF synergistically
increased the expression of Snail. Because Snail represses E-cadherin expression, this
finding explains the observed synergistic interaction between TGF1 and TNF on EMT
induction as indicated by the enhanced loss of E-cadherin and upregulation of N-cadherin.
However, WFA pre-incubation abrogated the cytokine-dependent increase in Snail
expression, and further prevented the loss of E-cadherin thus preventing EMT induction.
Overall, these findings suggest that the observed inhibition of EMT induction by WFA
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occurs at least in part due to the regulation of Snail expression by inhibiting Smad and/or
NF-B signaling pathways.
To further understand the potential mechanisms underlying the inhibitory effects of
WFA on TGF1/TNF-dependent EMT induction, we explored Smad and NF-κB
signaling pathways. Smad2 and Smad3 belong to a family of transcription factors that exist
as a Smad2/3 dimer in the cytoplasm in the inactive (dephosphorylated) form. However,
following TGFβ1 stimulation, these are phosphorylation, then bind to another cytosolic
protein called Smad4 and translocate to the nucleus where they stimulate the expression of
Snail [105]. Therefore, to determine whether WFA inhibits the activation of Smad
signaling, we measured the levels of total and phosphorylated Smad2, Smad3, and Smad4
in whole-cell, cytoplasm, and nucleus. Although WFA has already been shown to inhibit
Smad2/3 phosphorylation [107], our study provides additional evidence on the multiple
effects of WFA on Smad signaling. WFA inhibited the phosphorylation of both Smad2 and
Smad3, and thus prevented their nuclear translocation. Additionally, it appears that WFA
also targeted Smad3 and caused its degradation.
Several published studies have shown that WFA is a potent anti-inflammatory
activity and has been extensively studied for its effects NF-κB signaling mechanisms [22,
100, 110, 111]. In tumor cells, it is known that TNF activates the NF-κB signaling to
stimulate EMT induction, cell survival, proliferation, migration, and chemo-resistance [97,
109]. Mechanistically, the activation of NFB involves two major events; (1) IKK/
dependent phosphorylation and subsequent degradation of IκBα, the inhibitor of NF-κB
(P65), and (2) the phosphorylation and nuclear translocation of NF-B (P65). Data from
previous studies [110] conducted on fibrosarcoma and human embryonic kidneys cells
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indicated that WFA regulated NF-κB signaling by inhibiting the kinase activity of IKKα/β.
This resulted in decreased phosphorylation and degradation of IB, the phosphorylation
and nuclear translocation of NF-B (P65). Because TNF is known to induce EMT via the
NF-B pathway, we also assessed the effect of WFA on NF-B signaling. In agreement
with previous findings, we also observed dose-dependent inhibition of TNF-dependent
activation of NF-κB signaling in both A549 and H1299 cells. The phosphorylation and
degradation of IB was inhibited and was concomitant with decreased NF-κB
phosphorylation, nuclear translocation, and binding to DNA. These findings provide
additional supporting evidence of the inhibitory effect of WFA on NFκB signaling via
interference with IKK/β kinase activity.
In conclusion, using a combination of TGF1 and TNF to experimentally induce
EMT, our study demonstrates the inhibitory of WFA on EMT induction in A549 and
H1299 NSCLC tumor cells. Although detailed molecular mechanisms have not been
elucidated, our data provides a basis for the conclusion that WFA regulates EMT via the
regulation of Smad and NFκB signaling pathways. Together, the findings presented here
and in previous studies suggest that WFA is a promising antitumor agent that has
therapeutic potential in the treatment of metastatic NSCLC cancer. Additionally, our
observation that WFA was more potent against the highly invasive H1299 cells than the
moderately invasive A549 cell line, further strengthens this hypothesis.
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CHAPTER FOUR

REPEATED DOSING TOXICITY AND PHARMACOKINETICS OF WITHAFERIN A
IN SPRAGUE DAWLEY (SD) RATS
INTRODUCTION
Pharmacokinetics defines the processes of absorption, distribution, metabolism,
and the excretion of drugs in the body [112]. Currently, systemic chemotherapy using
cytotoxic agents remains the mainstay in the treatment of advanced NSCLC without
targetable mutations [9]. In NSCLC, multiple high doses of cytotoxic drugs are often
used to achieve the desired therapeutic response [16]. Many of the drugs used have a very
narrow therapeutic window and require precise therapeutic dose monitoring to minimize
the risks for toxicity. Traditionally, the dosing of NSCLC patients with various standard
chemotherapeutic agents is based on the assumption of a linear relationship between body
surface area (BSA) and clearance (CL) or volume of distribution (Vd) [113]. However,
remultiple clinical trials [112, 114] have shown that this is not true and that most
anticancer agents show interindividual pharmacokinetic variabilities. For example,
systemic exposure (AUC) after standard doses of paclitaxel varies by up to 10-fold
between patients [112]. Moreover, NSCLC patient populations are often very diverse and
complex, which creates the need for explicit drug dosing recommendations.
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The high variability of the pharmacokinetic properties of cytotoxic anticancer
drugs in patient populations make it very difficult for oncologists to predict individual
clinical responses in patients [112]. Moreover, with variable pharmacokinetics comes
an increased risk of both toxicity and sub-therapeutic dosing, leading to compromised
clinical efficacy [114]. On the other hand, if a drug has well-characterized
pharmacokinetic properties, it is possible to decrease interindividual pharmacokinetic
differences, minimize toxicity and enhance clinical efficacy by tailoring doses to the
individual patient (the so called individualized dosing) [12, 48]. Therefore, to enhance
clinical efficacy, it is important to characterize the toxicity and pharmacokinetics of new
anticancer agents early enough in the drug discovery process to provide a framework for
designing safe and efficacious dosing schedules.
Withanolides are a novel class of bioactive compounds that have shown multiple
pharmacological activities [115]. Withaferin A (WFA) is the most prominent member of
this class of compounds and has emerged as a potential therapeutic agent for cancer [22,
24]. Chemically, WFA is a plant-derived steroidal-lactone that was first isolated from the
alcoholic extracts of the Ayurvedic medicinal plant Withania somnifera [23, 24, 26]. In
literature, there is a growing body of in vitro and in vivo preclinical data to demonstrable
the efficacy of WFA against NSCLC [62, 83], breast [31, 35], cervical [66], prostate [39,
94], pancreatic [67], renal [116], B-cell lymphoma [68] and ovarian cancers [43].
Mechanistically, it has been shown that WFA targets heat shock proteins [117], vimentin
[31], NFkB [83], IKKβ-kinase [118], STAT3 [22], Blc2, cyclins, EGFR, and PAR-4 [30,
94]. Together, these varied molecular targets allow WFA to disrupt multiple cellular
processes such as proliferation, migration, invasion, and metastasis that are critical in the
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tumorigenesis of NSCLC cells [22]. Unfortunately, despite its demonstrable antitumor
efficacy in multiple models, WFA is currently stuck at the preclinical testing stage mainly
due to the lack of toxicity and pharmacokinetics data. There is very limited reliable data on
important disposition parameters of WFA such as; metabolic stability, plasma protein
binding, erythrocyte partitioning, excretion properties, and clearance.
In the present study, the objectives were to; (1) determine the potential repeated
dose toxicity, and (2) determine the preclinical pharmacokinetic properties of WFA.
Briefly, the sub-chronic toxicity of WFA was assessed for three doses (4, 8, 12 mg/kg) of
WFA in male SD rats following 28-days of repeated oral dosing. The toxic endpoints
consisted of an evaluation of changes in total body weight gain, food intake, hematological
and biochemical parameters. On this regard, our data indicate that up to 12 mg/kg of WFA
was safe and well-tolerated in male SD rats after oral administration. No significant
changes in total body weight, body weight gain, hematological and biochemical parameters
were observed. To study the pharmacokinetics of WFA, we first developed a highly
sensitive analytical method for the quantification of WFA in plasma and tissues. In this
method, we used HPLC as the chromatographic separation technique coupled to MS/MS
for detection and quantitation. This analytical method was successfully developed and
applied to determine the pharmacokinetic properties of WFA after administration of a
single bolus (i.v.) dose (10mg/kg) in male SD rats. In agreement with previous studies[31],
WFA displayed linear pharmacokinetics, with very rapid distribution and elimination from
plasma, and the concentrations fell below the detection limit within 2 h. Further, WFA
displayed high plasma protein binding and rapid intrinsic clearance in liver microsomes.
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MATERIALS AND METHODS
Chemicals and reagents
Withaferin A (Mol. Wt 470.61, purity > 95% HPLC) was kindly provided by 3P
Biotechnologies (Louisville, KY, USA). Dimethyl sulfoxide (DMSO, Cat #13390) was
purchased from Electron Microscopy Sciences (Hatfield, PA, USA). Pooled SD rat liver
microsomes were purchased from ThermoFisher (Kansas City, KS). Prednisolone
analytical standard (Mol. Wt. 360.44, Cat#46656) was purchased from Sigma (Sigma–
Aldrich, St Louis, MO, United States). In addition, acetonitrile, methanol, and ultrapure
HPLC-grade water were purchased from Sigma Aldrich (St. Louis, MO, USA).

Animals

Male SAS Sprague Dawley (SD) rats (150-200 g) were purchased from Charles River
Laboratories. These rats were housed individually or as a maximum of 3 rats/cage in a
temperature-controlled room (25 °C) with a 12-h light/dark cycle. The rats were allowed
access to purified AIN-93M diet and water ad libitum The research protocols involving the
use of animals were approved in advance by the Institutional Animal Care and Use
Committee (IACUC#17041).
Sub-chronic toxicity of WFA in male SAS SD rats
In this study, a total of 20 male SAS SD rats were used to evaluate the potential
toxicity of WFA following repeated oral dosing. Prior to the initiation of treatments, the
rats were allowed a minimum of 7-days acclimation period and then randomly divided into
4 experimental groups (n=5/group). To the first group, we administered a drug-free vehicle
(0.1 M β-hydroxypropyl cyclodextrin) in an equivalent volume with drug-treated rats. In
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the remaining 3 groups, rats were administered with 3 escalating doses of WFA (4, 8, 12
mg/kg). For the vehicle and all experimental groups, the rats were orally administered with
treatments three times per week for a total of four weeks (28-days). To assess the potential
toxicity of the treatments, several toxic endpoints were determined. Firstly, we observed
the rats daily for clinical signs of toxicity such as overall activity and isolation, breathing
rate, fur coat, eye color, and discharge. Before dosing (3 times/week), the body weights for
all rats as well as the amount of food per cage were recorded. After 28-days, the study was
terminated and all the surviving rats were humanely sacrificed by CO2 asphyxiation. All
blood from the carcasses was collected via cardiac puncture and selected organs (liver,
kidneys, lungs, spleen, brain, pancreas, gut, heart) were dissected out. The blood samples
for each rat were divided into two sub-samples and separately subjected to hematological
and biochemical clinical investigations (Antech Diagnostics). Some of the hematological
parameters evaluated included; total white blood cell counts (WBC), neutrophils,
lymphocytes, monocytes, eosinophils, basophils, total erythrocyte counts (RBC),
hemoglobin (Hb), hematocrit (HCT), and platelet count (MPV). For serum clinical
chemistry, the following parameters were determined: albumin, alkaline phosphatase
(ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin
direct, bilirubin total, creatinine (Cr), total protein, and blood urea nitrogen (BUN).
Furthermore, the selected tissues were weighted and random samples for each organ were
fixed in 10% neutral buffered formalin and sent for histopathological analysis.: For each
body organ removed, the absolute organ weight (g) was used to calculate the relative organ
weight with respect to the total body weight of each rat.
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HPLC-MS/MS conditions for analysis of WFA
The detection and quantitative analysis of WFA were performed on an Agilent 6550
iFunnel Q-TOF with Agilent JetStream equipped with an Agilent 1290 Infinity uHPLC
(Agilent Technologies, Santa Clara, CA, USA). For each sample run, 6 ul of sample was
injected onto a Zorbax Extend C18, 2.1 x 50 mm, 1.8-micron column(Agilent) kept at 40 º
C. The mobile phase was; A: 0.1% formic acid in water, B: acetonitrile. The mobile phase
gradient: 0-4 min 80% A to 5%A, 4-10 min held at 5%A, 10-12 min 5% A to 80%A. The
eluant was diverted to waste for the first 4 min of the run. High-resolution spectra were
obtained in the positive mode with a source gas temperature of 225 ºC, sheath gas
temperature of 375 ºC with a flow rate of 11 L/min. The MS spectra were obtained in the
mass range of 300-600 m/z and 90-600 m/z in the MS/MS mode. We used a fixed collision
energy of 20 for targeted MS/MS analysis. The precursors chosen were m/z 471 for WFA
and m/z 361 for the IS. For WFA, m/z 95 was used for quantification and m/z 281 and 299
were used as qualifiers. For the IS (prednisolone), m/z 147 was used for quantification
with ions 325 and 343 used as qualifiers.
Preparation of WFA Standard Solutions
Stock solutions of WFA and prednisolone were prepared by dissolving known
amounts of each agent in methanol. Standard solutions of WFA and prednisolone for
HPLC-UV analysis were diluted to final concentrations of 0.3 – 40 µg/mL while for HPLCMS/MS analysis, the standards were diluted to final concentrations of 0.5 – 5000 ng/mL.
Calibrations standards were prepared by spiking known amounts of WFA in blank plasma
or tissue matrix.
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Plasma and tissue sample preparations

To determine WFA concentration in plasma, aliquots (100 µL)of plasma were
mixed with 100 µL internal standard solution (100 ng/mL prednisolone) followed by the
addition of 800 µL of ice-cold acetonitrile. The mixture was vortexed vigorously for 1 min
and then centrifuged at 10, 000 x g for 10 min at 4 °C. The supernatants were carefully
transferred into 2 mL silanized glass tubes and dried completely under vacuum. The
residues were reconstituted in 100 μL of methanol, filtered and transferred to 1.5 mL HPLC
vial for analysis of the concentrations of WFA by HPLC-MS/MS method. Similarly, to
prepare tissue samples, about 1 g of tissue was homogenized in 3 mL of ice-cold 0.9%
saline solution. Then, for every 1mL of tissue homogenate, 100µL of IS solution was added
followed by the addition of 4 mL of ice-cold acetonitrile, vortexed vigorously for 1 min
and then centrifuged at 8,000 x g for 10 min. The supernatant was carefully separated from
the tissue debris, transferred to a new tube using a pipette and dried completely under
vacuum. The residues were reconstituted in 1 mL of acetonitrile: water (8:2) and loaded on
to Captiva-EMR lipid SPE cartridge (Agilent Technologies). The samples were allowed to
flow under gravity and followed by application vacuum to dry the cartridges. The eluent
was dried completely and then reconstituted in 100 µL of methanol prior to HPLC-MS/MS
analysis.
Plasma pharmacokinetics of WFA in male SD rats
To determine the plasma pharmacokinetic properties of WFA, male SAS SD rats
were cannulated in the right jugular veins with polyethylene cannulae. The surgery to insert
cannulae was performed on rats at Charles River Laboratories prior to the purchase and
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delivery of the rats. Following surgery, the rats were allowed to recover for one day and
then shipped overnight to the study site. In addition, the rats were allowed one more week
of acclimation period during which they were allowed free access to water and purified
AIN-93M diet ad libtum. On the day of the study, rats were administered with 10 mg/kg
(1 mg/mL in 0.1 M β-hydroxypropyl cyclodextrin) as a single bolus intravenous dose (<1
min injection) via the lateral tail vein. Serial blood (200 µL/time point) samples were
collected at 0, 5, 15, 30, 45, 60, 90, 120, 240, 360 and 480 minutes into heparinized tubes.
The blood samples were processed to obtain plasma by centrifuging for 15 min at 2000 x
g and stored at -80°C until analysis for WFA concentration using HPLC–MS/MS method.
The concentration-time data of WFA in male SAS SD rats were subjected to noncompartmental analysis (NCA) using Pheonix WinNonLin 8.1 software (Pharsight, CA,
USA). The following parameters calculated: AUC0-t, AUC0-, t1/2, total plasma clearance
(CL), mean residence time (MRT).

Protein binding of WFA in SAS SD rat plasma
The binding of anticancer drugs to plasma proteins significantly affects their
disposition kinetics and therapeutic efficacy [112]. Therefore, the objective of this study
was to determine the fraction of WFA bound to plasma proteins in SAS SD rat plasma.
Protein binding of WFA in freshly collected plasma was determined by ultracentrifugation
method for separating bound and unbound drugs using the Centrifree Ultrafiltration device
(Millipore, USA) with a 3000-molecular cut-off. Initially, we determined that the nonspecific adsorption of WFA on to the filter membrane by dissolving known amounts of
WFA in PBS (5% DMSO) and then determining the concentration of WFA before and after
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centrifugation. Then, for plasma protein binding capacity, aliquots of freshly collected
plasma (500 µL) SD rat plasma were spiked with known amounts of WFA in triplicates.
The samples were thoroughly mixed and incubated at 37°C for 30 min. The samples were
transferred to the Centrifree Ultracentrifugation device and centrifuged at 3000xg for 20
min. After centrifugation, the concentration of WFA was determined in the pre- and post
centrifugation samples (ultrafiltrate). The unbound fraction of (fu) of WFA was calculated
as: fu = (concentration of drug in ultra-filtrate/concentration in a pre-centrifuged sample) x
100%.
The stability of WFA in SD rat liver microsomes
In this study, pooled frozen samples of SD rat liver microsomes (20 mg/ml) were
purchased from ThermoFisher Scientific (Cat # RTMCPL). To determine the stability of
WFA in microsomes, in a total reaction volume of 1000 µL, we used 25µL of 20 mg/mL
commercial liver microsomes, 4 µL of drugs (0.01, 0.1 and 1 µg/ml in methanol, 871 µL
of 0.1 M phosphate buffer (pH 7.4) and mixed using a shaker for 5 min at 37 °C. Reactions
were initiated by adding 100 µL of 10 mM NADPH solution to the mixture, and 100 μL of
the reaction solution will be collected at different time points (0, 5, 15, 30, 60, 90 and 120
minutes). At each time point, the enzymatic reactions were stopped by the addition of 4 volumes of cold acetonitrile to precipitate the proteins. The samples were dried under
vacuum and reconstituted in 100 µL of methanol and analyzed for WFA concentration by
HPLC-MS/MS. The concentrations of WFA at the start (t=0) were considered as reference
and used to calculate percent remaining WFA with respect to t=0. The WFA/IS peak area
ratios were plotted against incubation time curves ton estimate the in vitro half-life (t1/2).
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The apparent intrinsic hepatic clearance was calculated as previously described [119] using
the following formula:

Elimination rate constant (k) = (-gradient)

Half life (t1/2), min =

0.693
k

V (µL/mg) =

Volume of incubation (µL)
Protein in the incubation (mg)

Intrinsic Clearance (CLint) (µL/min/mg protein) =

V x 0.693
t1/2

Hepatic intrinsic clearance (CLin, app) = CLmicrosome x [microsome weight (g) /liver weight
(g)] x [Liver weight (g)/body weight (kg)]

Statistical analysis
Statistical analysis was performed using GraphPad Prism 8.0 (Sandiego, CA, USA).
Plasma concentration-time data was subjected to non-compartmental analysis (NCA) using
the intravenous bolus model in Phoenix WinNonLin 8.1 (Pharsight, NC, USA). The
pharmacokinetic parameters for WFA were generated from individual serial
concentrations. The data are presented as means ± standard deviation (SD). Where
applicable, data comparisons between two groups were made using Student’s independentsamples t-test and one-way analysis of variance (ANOVA). Statistical significance was set
to be p < 0.05.

88

RESULTS
Potential sub-chronic toxicity of WFA in male SD rats
In this study, we evaluated the safety of repeated dosing of 4, 8, 12 mg/kg WFA to
male SD rats for 28 days. All the rats were dosed succesifully with WFA for the 28 day
period. None of the rats in all the 3 dose groups showed any signs of acute toxicity or
morbidity during the study period. More importantly, no mortality of rats in either vehicle
or experimental groups was observed at any of the 3 dose levels of WFA. Comparatively,
there was a slight dose-dependent but non-significant increase in the overall body of rats
dosed with WFA when compared to vehicle-treated rats over the 28-day period (Fig. 4.1a).
This was also the case when we calculated the percent body weight gain in the groups of
rats treated with WFA (Fig. 4.1b). However, while the percent body weight gains were
dose-dependent, all the calculated average weekly percent body weight gains were
statistically non-significant when compared to the vehicle-treated rats. Interestingly, data
from the food intake studies indicated an increase food uptake among the rats that received
WFA. Therefore, the observed dose-dependent increase in the body weights of rats that
were treated with WFA was correlated with the increase in food intake (Fig. 4.1c). Overall,
neither the changes in body weight gain nor food intake were statistically significant.
On dosing day 28 day, the toxicity study was terminated and all the rats were
humanely sacrificed by asphyxiation under CO2 asphyxiation. Blood and body organs were
collected at necropsy to evaluate systemic and histopathologic toxicity. There were no
significant changes in percent body weight ratios for liver (Fig. 4.1d), lungs (Fig. 4.1e),
kidneys (Fig. 4.1f) and spleen (Fig. 4.1g) of rats treated with WFA when compared to the
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vehicle control group. Analysis of whole-blood samples for complete blood count (CBC)
showed no significant changes in WBC (Fig. 4.2a), neutrophils (Fig. 4.2b), lymphocytes
(Fig. 4.2c) or monocytes (Fig. 4.2d). Similarly, the RBC (Fig. 4.2e), hemoglobin (Fig.
4.2f), hematocrit (Fig. 4.2g) or total platelet counts (Fig. 4.2h) were all comparable in the
WFA treated rats and vehicle-treated group. Serum biochemical analysis did not show any
significant changes in liver and renal function parameters. Total protein, albumin, blood
urea nitrogen (BUN), creatinine and total electrolyte concentrations (sodium, potassium,
chloride, and calcium) were non-signifcant (Fig. 4.3a). The enzymes AST, ALT, ALP,
GGT were all compared in the WFA and vehicle treatment groups. Histologic examination
of H&E sections of various organs revealed no visible microscopic changes in cellular
architecture, evidence of tissue necrosis or inflammation in liver, kidneys, and lungs.
Together, these findings show that repeated oral dosing of up to 12 mg/kg of WFA did not
cause any major gross or systemic toxicity and was well tolerated in male SD rats.
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Fig 4.1. Effect of WFA on body and organ weight. Male SD rats were orally administered with
vehicle (0.1 M β-hydroxypropyl cyclodextrin) or WFA (4, 8, 12 mg/kg) three times per week. (a)
Mean weekly body weights, (b) Percent body weight gains, and (c) Mean daily food intake.
Terminal organ weight ratios were calculated for each animal and presented as mean percent ratios
for (d) liver, (e) lung, (f) kidneys, and (g) spleen. All data were presented as mean ± SD for each
group of rats of 3 technical replicates. *p<0.05 when compared with vehicle control.
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Fig 4.2. Effect of WFA on hematological parameters. After 28 days, rats were sacrificed under
CO2 asphyxiation and terminal blood was collected by cardiac puncture. Mean; (a) Total white
blood cell counts (WBC), (b) neutrophils, (c) lymphocytes, (d) monocytes, (e) total red blood cell
counts (RBC), (f) hemoglobin (Hb), (g) hematocrit (HCT), and (h) total platelet counts. Data are
presented as mean ± SD for each group and were compared with the vehicle. No statistically
significant changes in hematologic parameters were reported at all dose levels of WFA.
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a.

b.

Fig 4.3. WFA did not cause biochemical or histological toxicity. (a) Serum was prepared
and subjected to biochemical analysis for total protein, albumin, blood urea nitrogen (BUN),
creatinine, AST, ALT, ALP, GGT, and electrolytes. (b) Representative photomicrographs of
H&E stained tissue sections were prepared from organs collected at the termination of study.
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HPLC-UV and HPLC-MS/MS analysis of WFA
For the purposes of detection and quantification of WFA in plasma and tissues, we
developed a highly sensitive and reproducible HPLC-MS/MS method. Previously, studies
conducted in this laboratory [120] have used prednisolone as internal standard (IS) based
on structural, chromatographic and extraction characteristics similarities with WFA.
Similarly, in the present study, we used prednisolone as the internal standard. The HPLC
chromatographic separation (1-10 µL injections) and UV detection (Fig. 4.4a), showed that
prednisolone (RT = 5.7 min) eluted before WFA (RT=6.3 min). The maximum UV
absorption for WFA was at 215 nm while the maximum absorbance for prednisolone was
at 244 nm. These two compounds, WFA (Fig. 4.4c) and prednisolone (Fig. 4.4d) displayed
linear responses in the mean peak area versus concentration curves, and the peaks for both
compounds were saturated at 100 µg/mL. In addition, the peak area ratios (WFA/IS) were
also plotted against WFA concentrations (Fig. 4.4e) and showed a linear relationship. The
lower limit of detection (LLD) by HPLC- UV was 0.1 µg/mL for WFA and IS in methanol.
Since the main objective was to determine the levels of WFA in plasma and tissues,
HPLC-UV was unsuitable for this analysis given the low UV absorbance of WFA (215
nm). Therefore, we optimized a new analytical method in which we used HPLC separation
coupled with MS/MS for detection and quantification of WFA levels. For both WFA and
IS, we observed maximum responses in the positive MS/MS mode (Fig. 4.4b). Therefore,
in positive MS/MS mode, we chose the m/z 471 and 361 as the precursor ions, 95 and 147
as the quantification ions for WFA and prednisolone, respectively. The m/z 281 and 299
ions were selected as qualifier ions for WFA while m/z 325 and 343 for prednisolone. The
peak area ratios of WFA/IS versus concentration were plotted (Fig. 4.4f)
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Figure 4.4. HPLC-MS/MS analysis of WFA. (a) Typical HPLC-UV chromatograpms obtained
at 215 nm and 244 nm showing the peaks for (1) prednisolone (IS) in red and (2) WFA in green
(volume of injection: 5 µL). (b) HPLC-MS/MS spectra for prednisolone and WFA. Standard curves
based on peak areas were generated for (c) WFA, (d) prednisolone. (e) Using a 10 µg/mL IS, a
standard curve based on peak area ratios (WFA/IS) was generated for WFA (0 – 40 µg/mL). (f)
Standard curve for WFA using HPLC-MS/MS was generated for WFA (0 – 500 ng/mL).
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Optimization of sample pre-treatment and method validation
Several methods are available for the extraction of small molecules from biological
matrices for quantitation purposes [121]. However, for each compound, there is need to
optimize the method that results in the best extraction characteristics of the target analyte.
In the present study, we developed and standardized a simple protein-precipitation method
for the extraction of WFA from rat plasma and tissues. We found that for adequate and
accurate quantitation, the sample preparation procedure required a matrix cleanup step to
improve on the instrument sensitivity. We used 100 ng/mL prednisolone solution as the
appropriate to monitor recoveries of WFA from plasma and tissue samples.
Initially, we investigated several crashing solvents to determine the best protein
precipitation solvents. Notably, we compared acetonitrile (ACN) alone, acidified ACN (1
% formic acid), and a mixture of ACN and methanol (MeOH) (1:1). For all these solvent
systems, we found out that there were no major differences in the recoveries of both WFA
and the IS. However, using ACN alone provided the cleanest supernatant and had the least
matrix interference in MS/MS (Fig. 4.5a). Therefore, we chose ACN as the extraction
solvent to precipitate the proteins and disrupt the protein binding of WFA in plasma and
tissue samples. It was determined that the best extract ratio of sample solution to ACN was
1:4 v/v. Next, when we compared the MS/MS responses of WFA in matrix versus without
matrix and found that there was more than 70 % ion suppression, particularly for the liver
samples. This significantly decreased the sensitivity and accuracy of the instrument and the
detection method. To decrease on the matrix interference, we used the Captiva EMR-Lipid
solid-phase extraction (SPE) to preferentially remove phospholipids (Fig. 4.5b). As a
result, Captiva EMR cartridges decreased the matrix effect from >70 % to 34 %.
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Step 1:
1. Weigh 1 g of tissue in 50 mL tube
2. Homogenize in 3 mL 0.9 % saline solution
3. Add 100 µL Internal Standard (IS) solution

1.
2.
3.
4.
5.

Step 2:
Add 4 mL ice-cold ACN for 1 mL of homogenate
Vortex vigorously for 1 min
Centrifuge at 8000 x g for 20 minutes
Transfer the supernatant to a new tube
Dry under vacuum

1.
2.
3.
4.
5.
6.

Step 3:
Re-dissolve the residue 2 mL of ACN/H2O (8:2)
Mix vigorously and centrifuge for 5 min
Load on to 3 mL Captiva EMR-Lipid cartridge
Allow the sample to elute under gravity
Apply vacuum to dry the cartridge
Dry the supernatant under vacuum

Step 4:
1. Re-constitute in 100 µL of MeOH
2. The samples are ready for LCMS/MS analysis

Fig 4.5. Tissue and Plasma sample preparation scheme for WFA analysis by HPLC-MS/MS.
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Fig 4.6. Sample matrix cleanup using Captiva-EMR Lipid SPE (a) Representative images
showing protein-precipitation using solvents (acetonitrile: ACN, acetonitrile + 1% formic acid;
ACN+1%FA, acetonitrile+methanol: CAN+MeOH (1:1). (b) Matrix clean-up was done using
Captiva-EMR lipid SPE cartridges. Standard curves for WFA spiked in (c) plasma, (d) kidney, (e)
lung, and (f) liver matrices.

98

Metabolic stability of WFA in SD rat liver microsomes
In this study, the in vitro stability of WFA in microsomes was evaluated using SD
rat microsomes at 37 °C. Briefly, 1 µM WFA was incubated with SD rat liver microsomes
(0.1 mg total protein) in a 200µL total reaction volume. A plot of peak area ratio (WFA/IS)
indicated a rapid time-dependent disappearance of WFA in the reaction mixture (Fig 4.7a).
The log-transformed data (Fig. 4.7b) showed a linear relationship between the peak area
ratios and time with a slope of -0.044. The elimination rate constant (k = - slope) of WFA
in rat microsomes was calculated as 0.044 and the half-life was 16 min. The intrinsic
clearance of WFA in SD rat liver microsomes was 88 µL/min/mg (Fig. 4.7c).

The unbound fraction of WFA in SD rat plasma
To determine the extent of plasma protein binding, known amounts of WFA were
spiked in freshly collected SD rat plasma and the unbound drug was separated from the
bound drug by an ultrafiltration method. Initially, we determined the non-specific binding
(NSB) of WFA to the filter membrane by dissolving WFA in PBS 0.5 µg/mL (5% DMSO).
After centrifuging, the NSB of WFA to the Centrifree Ultrafiltration® device membrane
was <3% (Fig. 4.7d). By comparing the concentration of WFA in plasma prior to
centrifugation (total), retentate and the filtrate, the fraction unbound (fu) of WFA was
approximately 5% (Fig. 4.7e).
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Fig 4.7. In vitro stability of WFA in liver microsomes and plasma protein binding. WFA (1
µM) was incubated with SD rat microsomes and the fraction of parent compound remaining was
determined by HPLC-MS/MS. The peak area ratios (WFA/IS) were plotted against time on (a)
linear and (b) logarithmic scales. (c) The half-life (t1/2) was 16 min and the in vitro intrinsic
clearance (Clint) was 88 µL/min/mg. Plasma protein binding in fresh SD rat plasma was determined
by ultrafiltration method. (d) Non-specific binding (NSB) was <3%. (e) Fraction unbound (fu) was
calculated from the amount of WFA in filtrate versus total WFA in precentrifuged samples as
approximately 5%.
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Pharmacokinetics of a single intravenous bolus dose of 10 mg/kg WFA in SD rats
The pharmacokinetic properties of WFA were determined in male SD rats
following the administration of a single intravenous bolus dose of 10 mg/kg WFA via the
lateral vein. The concentrations of WFA in freshly collected plasma were determined by
HPLC-MS/MS method as described in the methods section. The concentration-time plots
of WFa in plasma (Fig 4.8a) demonstrated a rapid decline in the concentration of WFA
with time. The mean concentrations of WFA in plasma rapidly fell below the limit of
quantification within 2 h after dosing. The log-transformed concentration data (Fig. 4.8b)
showed a linear relationship with time. The pharmacokinetic parameters of WFA were
estimated using Phoenix WinNonLin 8.1 (Fig. 4.8c). The maximum plasma concentration
was 907 ng/mL and was observed at the first sampling time point of 5 min after dosing.
The last measurable concentration, Clast, was 14 ng/mL at 2 h, with an AUClast of 15960
ng/mL*min and the AUC0-inf was 16709 ng half-life (t1/2) of WFA was 37 mins. The
estimated terminal plasma clearance was 598 ml/min/kg.
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5
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15960
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4.3
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37
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598

AUMC0-t (ng/mL * min *min)

352613

AUMC0-inf (ng/mL * min *min)

482466

Fig 4.8. Plasma pharmacokinetics of WFA in male SD rats. Plasma concentration (ng/mL)
versus time curve profile of WFA following a single bolus intravenous injection of 10 mg/kg WFA
in male SD rats. (a) Linear, and (b) Log-linear concentration versus time curves. (c) Noncompartmental analysis was perfomed using phoenix WinNonLin 8.1 to determine
pharmacokinetic parameters.
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DISCUSSION
Many of the cytotoxic drugs used in the systemic chemotherapy of NSCLC require
high doses to achieve clinically efficacious concentrations [13]. Traditionally, the dosage
calculations for anticancer drugs are based on body surface area (BSA) which is derived
from the body weight and height of patients [113]. However, this approach has proven
inadequate and fallacious since several studies have shown that factors such as protein
binding, metabolism, and clearance of drugs significantly affect the clinical efficacy of
cancer treatment [112]. Moreover, cancer patient populations are often highly complex and
varied in terms of age, presence of comorbidities or organ impairments [3]. In the current
era of personalized medicine [12], dosing of patients with such highly toxic agents requires
precise knowledge on the disposition characteristics of these agents. Today, the treatment
guidelines for NSCLC involve multi-drug combinations which are administered via
complex dosing schedules and sequences. Since there are limitations on the conduct of
pharmacokinetic studies in cancer patients, the pharmacokinetic properties of most anticancer drugs used currently are poorly characterized. Therefore, to better predict the
clinical efficacy of future cancer treatments, the potential anticancer agents must be well
characterized in the preclinical setting for their toxicity and pharmacokinetic properties
before studies are initiated in humans [9, 16].
Several published studies have demonstrated the potential therapeutic efficacy of
WFA against multiple cancer types [22]. However, there is still very limited data describing
the toxicity and pharmacokinetic properties of WFA to enable the design of appropriate
doses and dosing schedules for clinical studies. As such, for several decades, the anticancer
testing for the therapeutic efficacy of WFA is limited to preclinical studies. In addition,
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another major challenge to the study of the pharmacokinetics of WFA has been the lack of
reliable, accurate and reproducible analytical methods for the detection and quantification
of WFA in biological matrices. To address these challenges, we investigated the potential
repeated dosing toxicity and the single-dose preclinical pharmacokinetic profile of WFA
in male SD rats. Analytically, we have developed a highly sensitive HPLC-MS/MS method
for the detection and quantification of WFA in plasma and tissues. In our studies, we have
successfully applied this method to study the pharmacokinetics of WFA in males SD rats.
Ealier studies investigating the toxicity of WFA in experimental animals have been
based on observation of animals dosed with standardized extracts of W. somnifera.
Notably, studies have shown that alcoholic extracts of W. somnifera extract (up to 2000
mg/kg) were non-toxic to Wistar rats after 14-days repeated oral dosing [122]. Similar
studies have reported no signs of systemic or histological toxicity following repeated subchronic dosing of WFA in mice [123, 124]. Although it is evident that extracts containing
WFA have been evaluated for their toxicity, the extracts used in these studies contained
<5% total WFA (% w/w). Contrastingly, we have investigated the potential toxicity of pure
WFA (>95% purity) in male SD rats. In agreement with previously published studies, the
findings presented here show that orally administered WFA is essentially non-toxic to male
SD rats. While we observed a slight dose-dependent increase in body weight in the groups
of rats receiving WFA, these changes were nonsignificant. Moreover, evaluations of the
average food intake indicated that the observed body weight gains were correlated with
higher food intake. More importantly, systemic data did not reveal any evidence of bone
marrow suppression since parameters such as total RBC, WBC, Hb, and HCT were all
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comparable to vehicle-treated rats. Therefore, the doses (4, 8, and 12 mg/kg) of WFA that
we used in the present study were generally well tolerated and safe in male rats.
One major hindrance to the study of the pharmacokinetics of WFA has been the
lack of appropriate analytical methods. In literature, there are a few HPLC and HPLCESI-MS/MS methods for the detection of have been published [125-127]. It has been
reported that these methods could detect and quantify WFA in plasma up to a lower limit
of 50 ng/mL. Unfortunately, we failed to reproduce these methods as many did not include
sufficient experimental details. Whereas there are methods for detection of WFA in plasma,
limited information is available for the detection of WFA levels in tissue organs such as
liver, lungs, and kidneys. Moreover, during our preliminary studies, we compared the effect
of the matrix from plasma to that of other tissues and found that tissue matrices, especially
from the liver significantly suppressed ionization and subsequent detection of WFA by LCMS/MS conditions. Therefore, while the authors [125] argue that the published methods
could successfully be applied to quantify WFA in plasma, the methods were not applicable
to tissues. Recently, studies done and published from this laboratory reported a liquidliquid extraction method for the detection and quantification of WFA in tissues. Along the
same lines, we have made improvements to this method by adding a solid phase matrix
clean-up step instead of liquid-liquid sample preparation.
During our preliminary sample preparation studies, we investigated multiple
protein precipitation solvents to determine the most suitable of WFA. Though sample
preparation was adequate for both methanol and acetonitrile, the supernatants from samples
prepared with methanol were found to be turbid and the protein pellets were quite unstable.
Therefore, sample preparation with methanol (100% or 50%) was deemed unsuitable for
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the extraction since it produced significant matrix interference with the analytical
conditions. On the other hand, acetonitrile produced much better response and was selected
as the crushing solvent for sample preparation in subsequent studies. Further, in our
analysis, whereas protein precipitation with acetonitrile eliminated most proteins, there was
still significant interference on the ionization of WFA from lipids and phospholipids in the
extracted samples. To address this challenge, we examined several SPE methods for matrix
removal and found that the Captiva EMR-lipid cartridges (Agilent Technologies), which
are specially made for the removal of phospholipids. Intriguingly, this step significantly
improved the sensitivity of LC-MS/MS detection conditions and by applying a 10-fold
concentration of the original samples (by reconstituting samples (1 g tissue or 1 mL
plasma) in to 100 µL final volume, we improved the detection of WFA to up to 5 ng/g of
tissue or 1 ng/ml of plasma. Our recovery of both WFA and internal standard was greatest
from plasma samples (>80%) and lowest in liver samples (approx. 75%).
After developing the analytical method, we next investigated the pharmacokinetic
properties of WFA in SD rats. Previously, studies conducted in mice have investigated the
pharmacokinetics of WFA [31, 128]. However, whereas plasma pharmacokinetics were
investigated after oral administration in these studies, no data on protein binding capacity
or metabolic stability in microsomes are reported. Therefore, in our studies, we investigated
both the plasma protein binding capacity and metabolic stability of WFA in liver
microsomes in SD rats. Our data show that WFA displays a high protein binding capacity
in rat plasma resulting in a with a very low fraction unbound (fu). Since pharmacokinetic
properties such as hepatic metabolism, clearance, and volume of distribution are heavily
dependent on to the unbound fraction of drugs there is a significant potential of WFA to
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interact with drugs that show similar protein binding characteristics. In addition, WFA
displayed a high intrinsic hepatic clearance (>80 µl/min/mg) indicating that the liver plays
a critical role in the clearance of WFA from the body. Further, based on our plasma
concentration-time data, we show that WFA has linear pharmacokinetics in SD rats.
Following intravenous bolus administration, there was very rapid distribution and
clearance of WFA from plasma. There was a high volume of distribution greater than the
total body water indicating the extensive distribution of WFA in tissues. Since
concentrations of WFA fell below the limit of detection in 2 h, it appears slow intravenous
infusions would be the best mode administration. The observed short terminal plasma
t1/2 was in tandem with the observed rapid intrinsic clearance of WFA in rat microsomes
indicating the potential role of the liver in the clearance of WFA. Since urine was never
collected in the present studies, we did not determine the renal clearance of WFA.
Nonetheless, our observed plasma pharmacokinetic parameters were similar to those
obtained in mice after intraperitoneal and oral dosing of WFA.
In conclusion, WFA is a promising antitumor agent for the treatment of multiple
types of cancers. In the present study, we have investigated the potential oral toxicity and
preclinical pharmacokinetic properties of WFA SD rats. We conclude that oral dosing of
up 12 mg/kg of WFA was safe and well-tolerated without any signs of gross or systemic
toxicity in male SD rats. Further, WFA displays a high protein binding capacity to plasma
proteins indicating a potential for drug-drug interactions. Moreover, WFA displayed rapid
clearance in liver microsomes and plasma indicating that slow continuous infusion would
be the most appropriate mode of administration. Further studies to determine the tissuedistribution of WFA, particularly in the tumor-bearing animals are highly recommended.
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CHAPTER FIVE
OVERALL DISCUSSION, SUMMARY, AND CONCLUSIONS
Lung cancer remains the leading cause of cancer-related deaths among both men
and women worldwide, and in the United States. NSCLC contributes to 85-90% of all lung
cancer cases and has an overall survival rate of 15% after five years. The major reason for
the dismal prognosis of NSCLC is that 60-70% of patients are diagnosed when the disease
is at an advanced stage. As such, the tumors in many NSCLC patients are not amenable to
curative surgery and most of the patients succumb in less than one year after diagnosis.
Thus, systemic chemotherapy remains the only viable treatment option in the neoadjuvant,
adjuvant or palliative setting for advanced NSCLC.
Recently, there has been a paradigm shift in the treatment approaches for advanced
NSCLC. This was mainly prompted by the landmark discoveries of molecularly targeted
drugs and immunotherapies for NSCLC. However, despite these advancements, only
marginal improvements in progression-free survival but not overall survival have been
reported. Besides the high cost of therapy, targeted and immunotherapies only benefit
select groups of patients that fit a strict inclusion. Therefore, for the majority of NSCLC
patients, systemic treatment involves the administration of multiple cycles of high doses of
cytotoxic agents. Currently, cisplatin (cis-Pt) alongside paclitaxel (PAC) is the front-line
treatment regimen in the clinic for stage IIIB-V metastatic NSCLC [11, 129]. However,
chemoresistance, metastasis, and dose-limiting toxicities limit the therapeutic efficacy to a
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maximum of 14 months. In this doctoral thesis, we leverage the ability of WFA, a highly
efficacious plant-derived steroidal lactone to enhance the chemotherapeutic efficacy of
PAC against NSCLC. The main hypothesis was that WFA alongside PAC is a highly
synergistic approach, which shows greater antitumor efficacy than the current platinumbased chemotherapies. To test this hypothesis, we designed experiments to; (1) explore the
synergistic combination of PAC and WFA against human NSCLC cells, (2) determine the
effect of WFA on epithelial to mesenchymal transition (EMT), (3) determine the safety
and pharmacokinetic properties of WFA in experimental animals.
To demonstrate the in vitro antitumor efficacy, we used two human NSCLC cell
lines, H1299 (large cell carcinoma) and A549 (adenocarcinoma). Firstly, we showed that
that WFA alone was active against the growth and proliferation of both H1299 and A549
cell lines. The effects of WFA were both doses- and time-dependent, with median
inhibitory concentrations in the sub-micromolar range. As reported previously [130, 131],
WFA increased the production of reactive oxygen species (ROS) and induced cellular
apoptosis in NSCLC cells. The cytotoxic effects of WFA blocked the thiol donors
dithiothreitol (DTT) and N-acetyl cysteine (NAC). Therefore, we conclude and provide
evidence for the hypothesis that WFA induced apoptosis in NSCLC via thiol-dependent
mechanisms [130]. Next, we performed multiple drug combination studies consisting of
two drugs of either PAC, cis-Pt or WFA to determine the most efficacious combination
against cellular proliferation. Our data show that the combination of PAC+WFA was more
efficacious than PAC+cisPt, or cisPt+WFA. There was a dramatic increase in the potency
and efficacy of PAC when combined with WFA at 1:40, 1:20 and 1:10 combinatorial ratios,
respectively. Importantly, pretreatment of cells with WFA increased the synergistic effects
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of PAC and WFA indicating a chemosensitizing effect of WFA on NSCLC cells to
standard chemotherapeutic drugs. Together, the data presented demonstrate that the use of
WFA alongside PAC is a very attractive and viable alternative therapeutic strategy, and
provides a strong rationale for further testing of this combination in animal models and
clinical studies.
Today, > 90% of deaths in NSCLC are directly attributable to chemoresistance and
metastasis [13]. This prompted us the investigate whether WFA alone or in combination
with PAC targets chemoresistance in NSCLC. First, we used both drug-sensitive and drugresistant cells to determine the effects on cellular proliferation and mechanisms of drug
resistance. Interestingly, our data show that PAC-resistant (TR-A549) cells were crossresistant to cis-Pt but not to WFA. These cells overexpressed the MDR1 protein, an
indicator that increased drug efflux was the main mechanism of resistance [73]. Further,
PDL-1 expression was upregulated while E-cadherin was downregulation suggesting a
strong link between EMT, drug resistance and immune evasion in NSCLC. Thus, it appears
that the resistance of TR-A549 cells to PAC was associated with an upregulation of drug
efflux mechanisms, immune evasion, and EMT. When xenografted in athymic nude mice,
WFA significantly inhibited tumor growth PAC-resistant cells. Moreover, WFA treated
downregulated the expression of MDR1 in PAC resistant cells. Mechanistically, WFA
inhibited EMT induction via the regulation of smad2/3 and NF-κB signaling in a dose- and
time-dependent manner. In summary, these findings strongly suggest that WFA is highly
active against both drug-sensitive and drug-resistant NSCLC cells and its ability to inhibit
EMT in NSCLC cells demonstrates the potential of WFA to prevent or delay the emergence
of chemoresistance and metastasis in NSCLC during treatment.

110

Also, while multiple studies have reported the therapeutic efficacy of WFA, there
is very limited data on its potential toxicity and pharmacokinetics. In this thesis, we
examined the toxicity of WFA in male SD rats. Previously, some studies [122] have
indirectly investigated the toxicity of WFA in mice and rats by administering standardized
alcoholic extracts of W. somnifera. However, the limitation was that the content of WFA
in these extracts was very low (<1% w/w), and considering the chemical complexity of W.
somnifera extracts, it is not possible to delineate the effects of WFA from other compounds.
In contrast, we have evaluated the potential toxicity of repeated oral dosing of highly pure
WFA (>95%, HPLC) and found that WFA did not cause any signs of toxicity in a 28-day
study. In our study, up to 12 mg/kg of WFA was given as three doses per week via oral
gavage and did not cause any changes in hematological, biochemical or histopathological
parameters. Next, a highly sensitive, reproducible and robust HPLC-MS/MS method for
the detection and quantification of WFA in plasma and tissue samples was developed. In
this method, WFA from plasma or tissues is extracted by simple liquid-liquid extraction
followed an SPE matrix cleanup step using Captiva-EMR lipid removal cartridges. While
other methods have been previously published [125], all these were not suitable for analysis
of WFA in tissue by LC-MS/MS due to significant ion suppression. Using our method, the
sensitivity of LC-MS/MS was increased up to 80% for the detection of WFA in tissue
samples.
To study the pharmacokinetic properties of WFA, we determined the plasma
protein binding capacity, in vitro clearance in microsomes, and the plasma pharmacokinetic
properties of WFA in male SD rats. Using in vitro methods, we demonstrate that WFA
displays a high plasma protein binding (>95%) capacity as measured by ultrafiltration.
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Interestingly, when incubated in liver microsomes, there was a high intrinsic hepatic
clearance of WFA (Clint: 88 µL/min/mg). In male SD rats, WFA displayed an instant
distribution phase and rapid clearance from plasma. Following a single bolus dose of 10
mg/kg, the levels of WFA were below the limit of detection within 2 h. Together, these
findings suggest that WFA has a high volume of distribution in tissues, a high protein
binding capability to plasma proteins and hepatic clearance is the main elimination route
for WFA. Overall, our studies demonstrate that WFA is well tolerated and safe following
repeated oral dosing in rats. We developed a detailed method for the determination of WFA
in biological matrices and have used this method to study the pharmacokinetic properties
of WFA in SD rats.
In future studies, it is important that the synergistic effects of PAC and WFA are
validated in animal studies before clinical studies can be initiated. It is well known that
PAC treatment induces chemoresistance and metastasis mechanisms in NSCLC cells.
Therefore, we recommend that studies be conducted to investigate whether WFA when
used alongside PAC, can prevent the emergence of chemoresistance and metastasis in
NSCLC. Furthermore, both PAC and WFA show high protein binding and clearance in
liver microsomes. Therefore, it is important to study the pharmacokinetics of PAC+WFA
to identify potential pharmacokinetic drug interactions.
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